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ABSTRACT 
 
The interaction between the tyrosine kinase receptor Flt3 and its ligand leads to 
signalling during the commitment of haematopoietic stem cells.  Constitutive 
activation of the Flt3/FL pathway is a key factor in enhanced survival and expansion 
in acute myeloid leukaemia (AML). Although there is extensive knowledge regarding 
mutations leading to the constitutive activation of Flt3 receptor activity, the molecular 
mechanisms underlying the regulation of the flt3 gene in HSCs, and how such 
mechanisms might be altered in leukaemia, are still poorly understood. Here, by 
using HSC and leukaemic cell lines, I locate several regulatory elements in the flt3 
locus by DNaseI mapping and have characterized their epigenetic environment. 
Analysis of the methylation and acetylation status of histones H3 and H4 around flt3 
cis-regulatory regions highlights a distinct combination of epigenetic modifications 
specific to AML cells in a region that distinguishes the Flt3- and Flt3+ stages of HSC 
differentiation. Moreover, I show the link between the in vivo binding of C/EBPα and 
c-Myb on regulatory elements and chromatin remodelling in the differential 
regulation of flt3 in leukaemic cells. Finally, I identify the histone modifiers TIP60 and 
CBP as potential mediators of the epigenetic regulation of flt3 in AML cells. 
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 1 
CHAPTER 1: INTRODUCTION 
 
1.1 The haematopoietic system 
The haematopoietic system is organized as a hierarchy of clonogenic cell types that 
differ in their abilities for self-renewal, proliferation and differentiation (Szilvassy, 
2003).  The apex of this hierarchy is represented by a population of cells, defined 
haematopoietic stem cells (HSCs), which are able to sustain blood cell production, 
generating mature cells committed along specific lineages of the blood, bone 
marrow (Constantinidou et al., 2006), spleen and thymus (Szilvassy, 2003; 
Szilvassy et al., 2003; Ho, 2005).  HSCs gradually lose self-renewal potential as 
they start to differentiate towards their immediate progeny, the multipotent 
progenitor (MPP).  These MPP cells lack in vivo self-renewal ability but have the 
capacity for multilineage differentiation (Adolfsson et al., 2001), giving rise to the 
common myeloid progenitors (CMP) and common lymphoid progenitors (CLP).  
CLPs populate the lymphoid compartment, which consists of B and T lymphocytes 
and natural killer (NKs) cells.  CMPs can develop along the six major 
haematopoietic lineages of the myeloid compartment, that is, 
megakaryocytes/platelets, erythrocytes, monocytes/macrophages, basophils/mast 
cells, eosinophils and neutrophil /granulocytes.  Dendritic cells (DC) can arise from 
both the CMP and CLP in response to specific stimuli (Iwasaki et al., 2005) (Figure 
1.1).  
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Figure 1.1 Schematic representation of the haematopoietic hierarchy. This 
figure represents the generation of mature myeloid and lymphoid haematopoietic 
cells from long-term haematopoietic stem cells (LT-HSC). ST-HSC: short term 
haematopoietic stem cells; MPP: multipotent progenitors; CMP: common myeloid 
progenitors: CLP: common lymphoid progenitors; GMP: granulocyte/macrophage 
progenitors; MEP: megakaryocyte/erythrocyte progenitors; Dendr: dendritic cells; 
Gran: granulocytes; Mono: monocytes; Meg: megakaryocytes; Eryth: erythrocytes; 
NK: natural killer cells. 
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Each of the myeloid and lymphoid cell types has got a specific function.  
Megakaryocytes are the cells responsible for the generation of platelets, which are 
essential for normal blood clotting.  Erythrocytes are the most abundant blood cell, 
their principal task consisting of the delivery of oxygen to the body tissues and 
removal of carbon dioxide.  Monocytes, macrophages and granulocytes 
(neutrophils, eosinophils and basophils) are phagocytic cells, which together with 
NK cells take part in both innate immunity and cell-mediated immunity.  Finally, the 
lymphoid cells, that is, B-cells and T-cells, are the cornerstone of the adaptive 
immune system.  
Terminally differentiated blood cells have a range of lifespans, which in humans 
varies from 1 day (neutrophils) to 120 days (erythrocytes), so that the maintenance 
of their number requires lifelong production of cells, from a very small number of 
stem cells.  Under physiological conditions, homeostasis of the haematopoietic 
system must be maintained, while in response to haematological stress, stem cells 
must undergo a burst of activity in order to replenish any blood lineage affected.  
Once the physiological conditions are restored, the stem cells must return to their 
normal steady state. 
1.2 Ontogeny of the haematopoietic system 
The complex process of haematopoietic development occurs in different sites during 
vertebrate embryogenesis according to the different demands of the developing 
organism (Bellantuono, 2004).  The first site of primitive haematopoiesis is the yolk 
sac (YS) (Auerbach et al., 1996), which at day 7.5 post coitum (dpc) is generating 
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mainly embryonic counterpart of megakaryocytes, macrophages and erythrocytes 
and non-haematopoitic cell lineages.  Embryonic megakaryocytes exhibit a lower 
degree of ploidy and an accelerated production of platelets compared to their adult 
counterparts.  Embryonic macrophages synthesise a different set of enzymes 
compared to those in the adult, while erythrocytes in the embryo are nucleated and 
express embryonic isoforms of haemoglobin (βH1 and ε).  Collectively, these cells 
ensure protection from infection and bleeding, tissue remodelling, removal of dead 
cells and efficient oxygen supply to the developing embryo. 
For several years, the YS was believed to be the only source of de novo stem cell 
formation, with the HSCs originating from the YS by differentiation of the mesoderm 
(Moore and Metcalf, 1970).  It was initially proposed that HSCs originated in the YS 
and migrated via the blood to colonise the foetal liver.  This idea was supported by 
the in vitro presence among the YS progenitors of spleen colony forming unit (CFU-
S), cells that are equivalent to multipotent myeloid progenitors (Moore and Metcalf, 
1970).  In earlier studies involving the generation of chicken-quail chimeras 
(Dieterlen-Lievre, 1975), it was observed that YS cells failed to support definitive 
erythropoiesis and haematopoietic precursors found throughout life were derived 
from an intra-embryonic source.  This source was localized to the dorsal level, which 
consists of the aorta and the developing urogenital system, in the Para-Aortic 
Splanchnopleura/Aorta-Gonado-Mesonephros (PAS/AGM) region.  In the early 
1990s the presence of progenitors at day 10 dpc capable of long-term reconstitution 
was discovered in the AGM region (Muller et al., 1994; Medvinsky and Dzierzak, 
1996).  Subsequently, Godin and colleagues isolated YS and PAS progenitors at 
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day 8.5 dpc that were capable of giving rise to multiple myeloid lineages and B-cells, 
introducing the idea that multipotent progenitors may arise simultaneously in the 
PAS and the YS (Godin et al., 1995); whether either or both of these tissues provide 
the HSCs that will colonise the foetal liver and the bone marrow, is still unclear 
although few years later it has been showed that only PAS progenitor cells are able 
to generate lymphoid cells (Cumano et al., 1996).  The adult haematopoietic system 
begins to form at day 10 dpc in mice in the foetal liver (FL), which will become the 
main organ where HSCs undergo expansion and maturation.  A large pool of 
multipotent progenitors expands in the FL, these cells being phenotypically 
characterised as AA4.1+Linlow or AA4.1+LinlowSca-1+, and representing 0.05% of 
cells at day 14 dpc.  Immediately after birth, the bone marrow is populated by 
haematopoietic cells from the FL, and becomes the predominant site for adult 
haematopoiesis (Mikkola and Orkin, 2006). 
1.3 The haematopoietic stem cell 
Since the existence of HSCs was proven by Till and McCulloch in 1961 (Till and 
McCulloch, 1961), these cells have become the best characterised stem cell type.  
HSCs not only have the ability to differentiate into mature blood cells, but also have 
the essential capacity to reproduce themselves, a process known as self-renewal 
(Siminovitch et al., 1963).  Through self-renewal, one or both daughter cells retain 
the exact developmental potential of the parental stem cell and thereby ensure the 
maintenance of a lifelong pool of stem cells.  “Asymmetric” division results in the 
generation of two distinct daughter cells, one identical to the “parent cell” and the 
other being slightly more committed and with an increased tendency to differentiate.  
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“Symmetrical” division, on the other hand, results in the production of two daughter 
cells that are either identical to the parental one or are both committed (Pina and 
Enver, 2007).  The balance between symmetric and asymmetric division is required 
both to support a fast and robust response to haematological stress and to maintain 
homeostasis (Wanger, 2002). 
Self-renewal requires careful regulation; hence, sustained commitment of stem cells 
without replacement would lead to depletion of the stem cell pool while excessive 
self-renewal could lead to leukaemia (Dick, 2003).  Moreover, self-renewal is 
influenced and regulated by the so-called stem cell niche, which profoundly affects 
the decision of stem cells to enter symmetrical or asymmetric division (Spradling et 
al., 2001; Li and Xie, 2005). 
Under normal conditions the majority of HSCs and many progenitors are quiescent 
in G0 phase of the cell cycle (Cheshier et al., 1999).  During haematological stress, 
such as bleeding or infection, the quiescent HSCs enter the cell cycle, undergoing a 
symmetrical division in order to generate more committed daughter cells in response 
to the substantial demand for one specific lineage (Horvitz and Herskowitz, 1992; 
Mayani et al., 1993).  When the stress ceases and the demand for blood cells 
returns to normal, the stem cell pool will be replenished by self-renewal.  Under 
normal physiological conditions, HSCs undergo asymmetric division in order to 
maintain blood homeostasis (Morrison and Kimble, 2006).  If the number of HSCs in 
the bone marrow stem cell pool exceeds the number required, they can enter into an 
apoptotic program (Domen, 2001) (Figure 1.2). 
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1.4 Phenotypic characterization of HSCs 
The stem cell compartment of the bone marrow includes a heterogeneous 
population of cells that can be divided into three subpopulations based on their 
ability to reconstitute the haematopoietic system of lethally irradiated mice.  The 
most immature fraction of the HSC compartment is the long-term stem cell 
population (LT-HSC), which has the greatest capacity for self-renewal and the ability 
of repopulate the haematopoietic system of irradiated mice for more than six months 
and to subsequently be serially transplanted into secondary recipients (Morrison and 
Weissman, 1994).  LT-HSCs generate their immediate progeny, short-term stem 
cells (ST-HSC), which are capable of multilineage commitment but have reduced 
self-renewal potential, are only able to repopulate irradiated mice for 6-8 weeks and 
lack the ability to be serially transplanted (Adolfsson et al, 2001; Christensen and 
Weissman, 2001).  The third subpopulation of the bone marrow stem cell 
compartment consists of MPP cells; these have no reconstitution potential and give 
rise to lineage-restricted oligopotent progenitors, the common lymphoid progenitors 
(CLPs) and the common myeloid progenitors (CMPs) (Kondo et al., 1997). 
Even though HSCs are present at a very low level in the bone marrow, it is possible 
to isolate them in nearly pure form based on their immunophenotypical 
characteristics.  HSCs consist of a population characterized by the lack of 
expression of lineage markers of granulocytes (Gr-1), macrophages (Mac-1), 
erythrocytes (Ter119), B-cells (B220), T-cells (CD5) and natural killer cells (CD8a).  
These lineage negative (Lin-) cells are further characterized by their expression of 
the stem cell antigen Sca-1 (Ly6A/E) and of the tyrosine kinase receptor c-Kit 
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(CD117) (Ikuta and Weissman, 1992).  The HSC population described as c-Kit+ Sca-
1+ Lin- (KSL) contains LT-HSCs, ST-HSCs and the MPPs described above, which 
can be discriminated based on the expression of CD34 (Osawa et al., 1996) and the 
tyrosine kinase receptor, Flt3 (Adolfsson et al., 2001).  Hence, LT-HSCs, ST-HSCs 
and the MPPs are respectively in the CD34-Flt3-, CD34+Flt3- and CD34+Flt3+ 
subfractions of the KSL population (Figure 1.3). 
 
 
 
Figure 1.2 Haematopoietic stem cell fate choices. This figure represents the 
haematopoietic stem cell fate choices in the bone marrow. The processes of 
expansion, commitment and homeostasists results in generation of two identical 
HSCs, two committed cells and the generation of identical HSC and one committed 
cell, respectively. HSCs and quiescent cells are represented in light blue, committed 
cells in read and cells entering the apoptotic program in black. 
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Figure 1.3 Phenotypic characterisation of haematopoietic stem cells. This 
figure represents the phenotype of HSCs with the KSL compartment and the 
subdivision in LT-HSC, ST-HSC and MPP based on the expression of surface 
antigens CD34 and Flt3. 
 
 
1.5 Aberrant haematopoiesis: Leukaemia 
Leukaemia is defined as a cancer of the myeloid or lymphoid blood cells, 
characterized by the rapid proliferation of abnormal cells that disturb the 
homeostasis of normal haematopoiesis (Sawyers et al., 1991).  Leukaemia includes 
a large spectrum of diseases and is clinically and pathologically divided into acute 
and chronic forms: 
• Acute leukaemia: Defined by the rapid progression and accumulation of 
malignant cells in the bone marrow.  Immediate treatment is required in order 
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to prevent malignant cells from entering the bloodstream and colonizing other 
organs.  Acute forms of leukaemia are the most common in children. 
• Chronic leukaemia: Usually characterised by the deregulation of relatively 
mature cells of a particular lineage.  This disease normally arises after a long 
latency, and it is often monitored for some time before treatment to ensure 
maximum effectiveness.  This is a disease that occurs predominantly in 
elderly people, but can theoretically occur in any age group. 
Leukaemias are classified into lymphoid or myeloid types according to the nature of 
the abnormal cells found in the blood: 
• Acute myelogenous leukaemia (AML) 
• Acute lymphocytic leukaemia (ALL) 
• Chronic myelogenous leukaemia (CML) 
• Chronic lymphocytic leukaemia (CLL) 
 
AML develops by the clonal expansion of primitive myeloid progenitor cells, termed 
myelobasts, as a result of genetic alterations affecting growth or maturation and 
differentiation.  Immature leukaemic cells, which have the ability to divide and 
proliferate but lack normal differentiation capacity, accumulate in the bone marrow 
leading to a severe impairment of normal haematopoiesis (Sawyers, Denny et al., 
1991). The accumulation of malignant cells affects the normal structure of the bone 
marrow and a consequent decrease in the production of red blood cells (anaemia), 
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platelets (bleeding disorders) and white blood cells (increased susceptibility to 
infections).  The general symptoms observed are fatigue, shortness of breath, 
bleeding and easy bruising, and elevated risk of infections (Lowenberg, Downing et 
al., 1999). 
According to the French-American-British (FAB) classification, AML is divided into 8 
subtypes, M0 to M7, based on the type of cell from which the leukaemia developed 
and its degree of maturity: 
• M0: undifferentiated AML 
• M1: myeloblastic without maturation 
• M2: myeloblastic with maturation 
• M3: promyelocytic 
• M4: myelomonocytic 
• M5: monoblastic or monocytic 
• M6: erythrocytic 
• M7: megakaryocytic 
AML is the most common acute leukaemia that affects adults, but is rare in 
childhood, with approximately 1000 new cases per year in the UK.  The incidence of 
AML increases with age, the median age at diagnosis being 63 years.  AML is a 
potentially curable disease, the primary treatment for which consists of 
chemotherapy.  Treatment is divided into two phases: induction (to achieve a 
complete remission by reducing the amount of leukaemic cells to an undetectable 
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level) and postremission or consolidation therapy (to eliminate any undetectable 
disease and achieve a cure).  Despite aggressive chemotherapy only one quarter of 
patients enjoy “life long disease-free” survival. For a patient with relapsed AML, the 
only potentially curative therapy is a stem cell transplant, which could either be 
allogeneic (using stem cells from a compatible donor) or autologous (using the 
patient’s own stem cells). 
1.6 Leukaemic stem cells 
The aberrant haematopoietic processes that lead to the accumulation of leukaemic 
blasts in the bone marrow are initiated by rare cells termed leukaemic stem cells 
(LSC).  The existence of LSCs, originally referred to as “leukaemia initiating cells”, 
was proposed over 40 years ago (Bruce and Van Der Gaag, 1963), although their 
identification and characterization has taken place largely in the last decade, 
initiated by the seminal work of Dick and colleagues, who purified the immature 
(CD34+CD38-) and committed cell populations (CD34+CD38+) of leukaemic blasts 
from AML patients and transplantated them into immunocompromised non-obese 
diabetic-severe combined immunodeficiency (NOD-SCID) mice (Bonnet and Dick, 
1997).  It was observed that only the immature fraction of leukaemic blasts could 
propagate the leukaemia and it became apparent that the leukaemogenic process 
was entirely dependent on a small subfraction of cells, with the properties of stem 
cells, including surface phenotypic characteristics (Lapidot et al., 1994; Bonnet and 
Dick, 1997). However, these findings are still the subject of debate and there now 
appears to be a greater heterogeneity in the surface antigen phenotype of LSCs. 
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The revised view of the LSC phenotype arose from the observation of the negative 
effect the CD38 antibody has on the engraftment ability of the AML repopulating 
cells in NOD/SCID mice (Taussig et al., 2008). Hence, it was shown that CD38-
coated committed sorted cells from AML patients are cleared by the residual innate 
immune system of the NOD/SCID hosts (Taussig et al., 2008; Taussig et al., 2010). 
Consistent with these observations, it was reported that CD34+CD38+ leukaemia 
blasts efficiently engrafted when transplanted into NOD/SCID mice treated with anti-
natural killer cell antibody (Hogan et al., 2002; Taussig et al., 2010).  
At present, there is an on-going debate about the origin of LSCs.  Since normal 
HSCs and LSCs share the ability to self-renew and proliferate, it has been 
hypothesized that LSCs derive from HSCs.  However, LSCs could also derive from 
more differentiated, or even mature cells, which have reacquired stem cell-like self-
renewal potential (Figure 1.4) (Bonnet, 2005b).  Whether one or both ideas are 
correct, LSCs have either sustained or reacquired self-renewal capacity as a result 
of accumulated mutations or epigenetic changes that affect haematopoietic 
differentiation (Bonnet, 2005a; Bonnet, 2005b).  Additionally, as a consequence of 
constitutive or deregulated activation of signal transduction pathways, LSC have 
gained proliferative or survival advantage, generally through activating mutations in 
RAS family members and in the receptor tyrosine kinases c-Kit and Flt3 (Passegue 
et al., 2003; Gilliland et al., 2004). 
Figure 1.5 summarizes those properties of LSCs that dictate the nature of 
leukaemia.  The prevention of differentiation is generally caused by fusion proteins, 
such as BCR-ABL and other AML-associated fusion proteins that activate aberrant 
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signalling pathways, which in turn interfere with the normal program of 
haematopoietic development.  An important feature of LSCs and a crucial event in 
their leukemogenic transformation is the increased survival that these cells have 
gained through the prevention of apoptosis.  Thus, the predisposition towards 
leukemogenesis could derive from activating mutations in the Bcl-2 family genes, 
which act as programmed cell death antagonists in response to apoptotic signals, or 
silencing mutations in Bax family members, which function to promote apoptosis.  
Furthermore, LSCs must possess an increased or constitutive self-renewal ability in 
order to perpetuate the disease, and this can be brought about through the 
activation of c-Myc or cyclin D1, Wnt, Notch and Shh signalling pathways, or via the 
upregulation of Hox genes (Figure 1.5) (Passegue et al., 2003).  
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Figure 1.4 Origin of leukaemic stem cells (adapted from “Normal and 
leukaemic stem cells”; Bonnet D. 2005). This figure illustrates how the leukaemic 
transformation process can happen in different cells. Panel A shows the 
transformation event occurring committed progenitor cells. Panel B indicates the 
origin of leukaemic cells from HSCs. 
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Figure 1.5 Leukaemic stem cell signalling pathways (adapted from “Normal 
and leukaemic haematopoiesis: Are leukaemias a stem cell disorder or a 
reacquisition of stem cell characteristics”; Passegue et al.; 2003). This figure 
depicts the deregulated signalling pathways that lead to leukaemia, showing the 
general mechanisms involved in the transformation process, such as impaired 
differentiation, increased cell survival, increased proliferation and increased self-
renewal. 
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1.7 Transcriptional regulation of haematopoiesis 
Regulation of the haematopoietic hierarchy from the stem cell through to the fully 
mature blood cells requires precise control of gene expression.  The importance of 
transcription factors in influencing cell fate relies on their ability to recognize specific 
DNA elements and recruit co-activators or co-repressors to the promoter and 
enhancer regions of the target genes.  Furthermore, transcription is a complex 
enzymatically driven process in which transcription factors may recruit of be 
recruited by specific proteins that mediate chromatin changes, therefore leading to 
either gene activation or silencing (Kouzarides, 2003). Diverse transcription factors 
are critical regulators of haematopoietic development and through specific 
combinatorial interactions establish the lineage- and stage-specific patterns of gene 
expression, ultimately defining cellular identity. 
1.7.1 Transcription factors involved in haematopoiesis 
Critical transcriptional regulators of haematopoiesis have been initially identified 
through the investigation of genes whose aberrant activation was causal for 
leukaemia (Orkin, 1995).  Indeed, many chromosomal aberrations or altered 
transcriptional programs targeting those genes result in the various haematological 
malignancies described above (Orkin, 1995; Zhang, 2008; Lionberger and Stirewalt, 
2009).  One of the aims of this thesis is to investigate the transcriptional regulation 
of the flt3 gene in HSCs.  Doing so will identify transcription factors that are known 
to exert their function in the bone marrow stem cell compartment where flt3 
expression has been shown to be critical.  In this section I describe the main 
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transcription factors associated with normal haematopoietic development that may 
be potential regulators of flt3 expression. 
1.7.1.1 SCL 
The transcription factor SCL, also known as TAL-1 (T-cell acute leukaemia-1), was 
initially discovered through its involvement at the site of chromosomal 
rearrangement in T-ALL (Begley and Green, 1999).  Mice lacking the expression of 
SCL die between E8.5 and E10.5 due to the inability to form blood cells in the YS, 
resulting in severe anaemia (Shivdasani et al., 1995).  Moreover, ES cells in which 
both alleles have been inactivated (homozygous knock out, SCL-/-) do not 
contribute to any definitive lymphoid or myeloid lineage cells in chimeras generated 
by the introduction into wt blastocysts.  Conditional gene deletion revealed an 
absolute requirement for SCL in the genesis of both primitive and definitive 
haematopoiesis, but its sustained expression appears to be dispensable for the 
maintenance of the HSC pool in the adult bone marrow (Porcher et al., 1996; 
Mikkola et al, 2003).  
1.7.1.2 LMO2 
Described as a partner of SCL, LMO2 has been found to be expressed at high 
levels in leukaemic blasts and is a common target of chromosomal rearrangement in 
ALL (Rabbitts, 1998).  Mice deficient in LMO2 die around E10.5 due to the 
abrogation of the formation of the erythroid cells in the YS.  As for loss of SCL 
function, LMO2-/- cells do not contribute to lymphoid and myeloid lineages in ES 
cells chimeras (Warren et al., 1994).  
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1.7.1.3 Runx1 
Runx1 (Runt-related transcription factor 1, also known as AML1 (Acute 
Myelogenous Leukaemia factor 1), has been shown to be a critical regulator of 
definitive haematopoietic development during embryogenesis (Okuda et al., 1996).  
It has been described to be strictly required for early haematopoiesis in the embryo, 
but like SCL is dispensable in the adult bone marrow.  The targeted disruption of the 
Runx1 gene results in embryonic death at E12.5-13.5, with no signs of definitive 
haematopoiesis (Okuda et al., 1996).  Conditional knock out experiments revealed 
the importance of Runx1 for megakaryocytic commitment, resulting in a decreased 
number of platelets, and B- and T-cell maturation (Ichikawa et al., 2004; Growney et 
al; 2005).  Additionally, Runx1 is one of the most frequently mutated genes, and a 
very common target of translocation in human acute leukaemia (Erickson et al., 
1992). 
1.7.1.4 CBFβ  
Initially identified as a gene involved in chromosomal rearrangement in AML 
(Miyoshi et al., 1991), CBFβ is the dimerisation partner of Runx1 (Downing, 
2001)oc.  Similar to the phenotype of Runx1 knock out models, mice deficient for the 
expression of CBFβ die in utero at E12.5-E13.5 due to the complete absence of 
haematopoiesis in the foetal liver, while YS erythropoiesis is unaffected (Wang et al; 
1990; Niki et al., 1997).  Miller and coworkers showed that controlled restoration of 
its expression re-established foetal liver haematopoiesis, although with a smaller 
number of primitive precursor cells (Miller et al., 2002). 
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1.7.1.5 GATA2 
Knock out mice for the zinc-finger transcription factor GATA2 die in utero between 
E10 and E11 due to severe anaemia and exhibit a drastic reduction in the number of 
haematopoietic progenitors (Tsai et al., 1994).  Erythroid progenitors are largely 
absent, and the number of macrophage progenitors is reduced. The analysis of 
AGM region also revealed a reduced number of HSCs (Ling and Dzierak, 2002). In 
addition, Rodrigues and colleagues described that mice haploinsufficient for GATA2 
have a low number of HSCs in the bone marrow and a reduced level of granulocyte-
monocyte progenitors (Rodrigues et al., 2005).  
1.7.1.6 c-Myb 
This is a key regulator of haematopoiesis. c-myb null mice are embryonic lethal at 
E15 due to severe anaemia, although embryonic erythropoiesis in the YS is  not 
affected, as indicated by the presence of primitive nucleated erythrocytes (Mucenski 
et al., 1991).  Definitive haematopoiesis in the foetal liver is drastically impaired, with 
the only mature haematopoietic cells present being megakaryocytes and 
macrophages (Mucenski et al., 1991).  Analysis of c-myb-/- embryos at E13 
revealed the presence of progenitor-like cells, although these cells were not able to 
differentiate into fully mature cells, indicating that c-myb is not essential for the 
generation of adult HSCs but is necessary for their expansion and differentiation 
(Sumner et al., 2000). 
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1.7.1.7 PU.1 
This is a member of the ETS family transcription factor and has been described as 
being essential in the specification of haematopoietic lineages.  It is highly 
expressed in myelomonocytic cells and in B-cells, with lower expression in HSCs 
and CMPs (Klemsz et al., 1990; Akashi et al., 2000).  The importance of PU.1 was 
revealed by the generation of knock out mice, which exhibited late embryonic or 
early neonatal death due to lack of B-cells and myelomonocytic development (Scott 
et al., 1994; McKercher et al., 1996). 
1.7.1.8 Ikaros 
This is a zinc-finger transcription factor that has been shown to be necessary for 
lymphoid specification (Georgopoulos et al., 1994).  To date, ten different isoforms 
of Ikaros have been identified, all of which share the dimerisation domain that is 
necessary for the interaction with other proteins, although not all the splicing 
variants have the zinc-finger domain that is necessary for the DNA binding (Sun et 
al., 1996).  Among the several mutant alleles generated, mice engineered for the 
deletion of the zinc-finger domain showed the most severe phenotypes, underlining 
the importance of Ikaros during lymphoid commitment.  The disruption of Ikaros 
results in the lack of both primitive and adult B- and T-cells (Winandy et al., 1999) 
and a decrease in LT-HSC repopulation capacity (Nichogiannopoulou et al., 1999). 
1.7.1.9 HoxA9 
Is a member of the homeobox gene family and has been extensively investigated 
because of its importance in both haematopoiesis and leukaemia (Argiropoulos and 
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Humphries, 2007; Hu et al., 2009; Novotny et al., 2009).  The targeted disruption of 
the HoxA9 gene resulted in a severe phenotype, involving the impairment of several 
haematopoietic lineages (Lawrence et al., 1997).  Furthermore, repopulation assays 
revealed that HoxA9-/- HSCs failed to reconstitute the bone marrow compartment, 
indicating its relevance in early HSC function.  In contrast, its overexpression 
strongly supports in vivo reconstitution, suggesting an important role in HSC self-
renewal (Thorsteinsdottir et al., 2002; Lawrence et al., 2005) 
1.7.1.10 Meis1 
This is a partner of HoxA9 with which it forms dimeric (HoxA9-Meis1) or trimeric 
(HoxA9-Meis1-Pbx1) complexes (Shen et al., 1997; Shen et al., 1999), and is 
frequently up regulated in cases of AML and ALL (Wang et al., 2006).  Meis1 null 
mice die at E14.5 due to severe haemorrhaging caused by the lack of 
megakaryocytes in the foetal liver.  Additionally, the total number of colony forming 
cells is dramatically reduced.  Meis1-/- cells fail to repopulate adult haematopoietic 
tissues, underlining the importance of this transcription factor in the self-renewal and 
proliferation of HSCs (Hisa et al., 2004). 
1.8 Chromatin structure and epigenetic regulation of 
haematopoiesis 
DNA is tightly packaged inside the nucleus of the cell as an intricate assembly of 
nucleic acid and small nuclear proteins, known as the nucleosome, which acts as 
the basic building block of chromatin. Chromatin can show different levels of 
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packaging, from the transcriptionally active “beads on a string” structure, in which 
the DNA is wrapped around the nucleosome, to a condensed higher order fibre 
associated with gene silencing (Kornberg, 1974).  The nucleosome consists of an 
octamer of histone proteins incorporating two copies of each of the histone core 
proteins H2A, H2B, H3 and H4, assembled as two H2A/H2B dimers and a H3/H4 
tetramer (Kornberg and Thomas, 1974; Luger et al., 1997) (Figure 1.6).  
Nucleosomes are joined together by a 60bp “linker DNA” fragment and sealed off at 
the entry and exit sites of the DNA by the histone protein H1, which functions to 
stabilize the structure of the chromatin. 
Both histone H3 and H4 have long flexible amino-terminal tails that protrude from 
the nucleosomal core; these tails are potentially subjected to a vast range of 
covalent modifications.  This “information” in the form of specific chemical groups 
exposed at the surface of the nucleosome can be “read” by specific effector 
proteins, leading to consequences either in terms of the structure or the function of 
the chromatin. The main modifications are methylation, acetylation, phosphorylation, 
glycosylation, sumoylation and ubiquitination (Margueron et al., 2005; Nightingale  et 
al., 2006).  
Normally the tight packaging of chromatin around silenced genes hinders almost all 
biochemical processes involving DNA.  Accumulating evidence suggests that genes 
that are about to be transcribed undergo a stepwise process of chromatin alteration, 
in which specifically recruited enzymes either modify the accessibility to chromatin 
or mark the histone proteins with covalent modifications.  In the former case, 
nucleosomes that normally block the accessibility of DNA binding proteins are 
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literally pushed away so that the naked DNA can become accessible to transcription 
factors.  The covalent modifications instead constitute a sort of “code” displayed on 
the histones that can then be read by other effector proteins, usually in the form of 
multienzymatic complexes, to modulate the pattern of gene expression (Turner et 
al., 1992; Strahl and Allis, 2000). 
 
Figure 1.6 Schematic representation of chromatin structure and post-
translational modifications. (from “Reading signals on the nuclkeosome with a 
new nomenclature for modified histones”; Turner BM. 2005). This figure provides a 
schematic representation of chromatin structure and shows the post-translational 
modifications occurring on the N-terminus of histone tails. The modifications shown in 
figure are lysine acetylation (Acetyl K, indicated by red dots), lysine and arginine 
methylation (Methyl R and Methyl K, indicated with blue and green dots, respectively), 
serine phospholation (Phos S, white square) and lysine ubiquitination (Ubiq K, orange 
square). 
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1.8.1 DNA methylation 
Since its discovery in the early 1980s, DNA methylation has been the most 
investigated and is the best understood epigenetic modification.  Catalysed by S-
adenosyl methionine-dependent DNA methyltransferase, this modification consists 
of the deposition of a methyl group on the carbon 5 of the cytosine ring, 
predominantly at CpG dinucleotides.  It has been demonstrated that DNA 
methylation, which is associated with gene silencing, is fundamental for 
development, being involved in many processes such as imprinting, X-chromosome 
inactivation and tumorigenesis (Bird and Wolffe, 1999).  Approximately 70-80% of 
CpGs are methylated in mammals, and the remaining unmethylated ones are 
generally located at gene promoters, in so-called CpG islands that are rich in CG 
content.  Normally, methylated DNA is not accessible for the binding of transcription 
factors but can interact with other proteins called methyl-CpG-binding domain 
proteins (MDBs) that recruit other chromatin modifying enzymes (such as the 
histone deacetylases), and thus confer to the chromatin a compact, more repressed 
conformation (Herman and Baylin, 2003).  The importance of this modification in 
developmental gene regulation is apparent from the demonstration that the 
disruption of genes coding for methyltransferases result in embryonic lethality.  
Furthermore, recent studies performed by Chen and coworkers have established a 
correlation between loss of DNA methylation and genomic instability (Chen et al.; 
1998).  During the cell cycle, methylation activity must be controlled and maintained 
in order to avoid the generation of unmethylated DNA daughter strands.  The loss of 
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methylation is a common feature during tumourigenesis, since one of its functions is 
to silence many tumour suppressor genes (Di Croce et al., 2002). 
1.8.2 Histone modifications 
The last decade has seen growing interest in histone modifications and the link that 
these modifications have with the “activated” or “repressed” state of chromatin.  
Particular modifications, such as lysine and arginine methylation or lysine 
acetylation, have attracted particular attention since several studies have 
established that actively transcribed genes are associated with increased 
abundance of these marks.  The information associated with the methylation status 
varies based on the residue involved.  Hence, di- and tri-methylation of histone 3 
lysine 4 (H3K4me2 and H3K4me3) and mono-methylation of histone 3 lysines 36 
and 79 (H3K36me and H3K79me) are generally enriched at the promoter of actively 
transcribed genes.  In contrast, the di- and tri-methylation of histone 3 lysines 9 and 
27 (H3K9me2, H3K9me3 and H3K27me3) and the mono-methylation of histone 4 
lysine 20 (H4K20me) are normally observed on genes that are transcriptionally 
silent (Margueron et al., 2005; Turner, 2005).  Recent publications have pointed to a 
dual role for the H3K9me2 modification, since it can also be associated with actively 
transcribed genes when present in combination with acetylation marks.  Acetylation 
status as well is a strong indicator of gene activity as demonstrated for the lysine 9 
of histone 3 (H3K9ac) and lysine 8 of histone 4 (H4K8ac) (Turner et al., 1992).  
Acetylated histones alter the interaction between DNA and the nucleosomes, 
conferring to the chromatin a more “open” configuration, thus increasing 
transcription factor accessibility (Turner, 2003). This covalent modification has 
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functional outcomes via two mechanisms: i) it leads to charge neutralization of the 
positively charged lysine and direct changes in the chromatin structure and ii) leads 
to the recruitment of proteins containing specialized acetyl-histone domains termed 
“bromodomain protein”. Bromodomain proteins and other chromatin remodelling 
proteins are specifically recruited to chromatin sites either prior to or as a 
consequence of transcription factors binding to DNA (Deuring et al., 2000; Lachner 
et al., 2001).  
These chromatin remodelling complexes play important roles in all the DNA-
dependent processes as they can translocate nucleosomes along the DNA 
repositioning or evicting them from the DNA in order to promote transcription 
(Becker PB, 2002).  On the other hand, these complexes can also repress 
transcription by inducing nucleosomes spatial changes and chromatin assembly 
(Clapier and Cairns, 2009). In the past few years many complexes have been 
characterised, among which ACF, Chd1, Mi-2 and NURF, and have been involved in 
detecting altered nucleosome positions and enabling the binding of the transcription 
factors to their cognate binding sites (Denslow and Wade, 2007). Moreover these 
dynamic changes in the chromatin structure have been shown to occur at specific 
gene cis-regulatory regions, as a consequence of transcriptional activation. 
Therefore, the binding of a transcription factor to the promoter of a given gene would 
result in the recruitment of a specific complex containing histone modifying enzymes 
and/or chromatin-remodelling proteins, which are responsible for the deposition of 
active histone marks and the repositioning of nucleosomes (Clapiers and Cairns, 
2009). Furthermore, Lefevre and colleagues have shown that the recruitment of 
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chromatin remodelers at promoters and enhancer regions, is associated with 
DNAseI hypersensitive site formation (Lefevre et al, 1999). DNAseI hypersensitive 
site mapping will be discussed in more details in section 2.4 and 4.3.  
The biochemical processes that lead to the marks mentioned above are reversible 
through the action of opposing classes of specific enzymes, that is, histone 
methyltransferases (HMTs) and histone acetyltransferases (HAT), are countered 
respectively by histone lysine demethylases (HKDMs) and histone deactetylases 
(HDACs). 
1.8.3 Mixed Lineage Leukaemia (MLL) family methyltransferases 
MLL family members are H3K4-specific methylases that, through ensuring the 
appropriate transcription of Hox genes, are strictly required during embryogenesis 
and haematopoiesis.  MLL is the mammalian homologue of Drosophila 
melanogaster Trithorax, a group of methyltransterases that positively regulate gene 
expression (Gu et al., 1992; Tkachuk et al., 1992).  Most MLL proteins display the 
typical HMT signature sequence, that is, the C-terminal SET (Su(var) 3-9 Enhancer-
of-zeste, Trithorax) domain.  
The 430kDa MLL multi-domain protein is cleaved by Taspase1 into a large 320kDa 
N-terminal fragment (MLLN) and a small 180kDa C-terminal fragment (MLLC).  After 
cleavage the two fragments move into the nucleus where they form a non-covalently 
associated heterodimeric complex.  MLLC contains the SET domain responsible for 
the methylase activity and a binding domain for the acetyltransferase CREB-binding 
protein (CBP).  MLLN on the other hand is composed of three “AT hook” motifs and 
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a CxxC zinc-finger domain homologous to the DNA methyltransferase DNMT1.  
Functional studies have suggested the involvement of these domains in the 
formation of MLL complexes (Nakamura et al., 2002; Hsieh et al., 2003; Slany, 
2005). 
Several studies have reported the association of MLL with other proteins, including 
WDR5, which is essential in maintaining the stability of MLL complexes, CREB-
binding protein and MOF, which both activate gene expression via their 
acetyltransferase activity, and the tumour suppressor protein Menin.  The latter has 
been shown to be essential in maintaining Hox gene expression, in particular that of 
HoxA9, for which it was demonstrated that in the absence of Menin its regulation by 
MLL was completely abrogated (Slany, 2005). 
A number of research groups have focused their attention on the role of MLL in 
haematopoiesis since it was reported that the targeted disruption of MLL results in 
embryonic lethality with severe deficiency in both yolk sac and foetal liver 
haematopoietic progenitors (Yu et al., 1995; Ernst et al, 2004). 
1.8.4 Polycomb group (PcG) proteins 
The Polycomb group constitutes another family of chromatin remodelling proteins 
that plays a pivotal role in silencing Hox gene expression during development, 
including a crucial role in the regulation of HSC self-renewal, proliferation and 
commitment (Lund and van Lohuizen, 2004).  Several recent publications have 
described how the Trithorax group (TrxG) and the PcG proteins act antagonistically 
as a binary epigenetic switch in regulating cell fate in haematopoiesis and other 
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biological processes.  The TrxG proteins are involved in the maintenance of active 
gene expression, while PcG proteins exert their function by repressing gene 
expression.  PcG proteins form multiprotein complexes, referred to as Polycomb 
Group Repressive Complexes 1 and 2 (PRC1 and PRC2).  PRC1 is composed of 
several polypeptides: Polyhomeotic (PH), Posterior sex combs (PSC) and Polycomb 
HPC1 and HPC2.  PRC2 is instead constituted by Extra sex combs (ESC), EED, a 
suppressor of Zeste domain SUZ12 and the EZH2 enhancer of Zeste.  It has been 
demonstrated that the EZH2 component of PRC2 methylates lysines 9 and 27 of 
histone 3, marks usually associated with inactive chromatin.  PRC1 appears instead 
to be involved in stabilizing the state of gene repression by recognizing the 
H3K27me3 mark deposited by the PRC2 complex (van der Vlag and Otte, 1999; 
O'Carroll et al., 2001; Cao et al., 2002; Kuzmichev, et al., 2004).  
1.9 Haematopoietic deregulation in leukaemia 
Many haematopoietic malignancies develop from perturbation of the molecular 
processes governing lineage specification and proliferation programs.  The hallmark 
properties of leukaemia, that is, differentiation block, hyperproliferation and inhibition 
of apoptosis, can result from a disruption of the transcriptional machinery (Orkin, 
1995).  Many transcription factors have been linked to leukaemia and, as already 
discussed above, were often identified initially through their association with specific 
types of diseases. 
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1.9.1 Runx1 
The disruption of Runx1 is a very common aberration in leukaemia.  Chromosomal 
translocations at the Runx1 locus have been extensively investigated since the 
RUNX1/ETO fusion gene is found in 40% of AML-M2 cases and the TEL/RUNX1 
fusion is associated with 20% of ALL (Harada et al., 2003; Harada et al., 2004).  In 
addition, many point mutations have been identified in the Runx1 gene, most of 
which alter the DNA binding capacity or transactivation activity of the protein (Osato, 
2004).  Recent studies have reported the association of point mutations that in 5-
10% of AML-M0 cases result in the formation of truncated proteins with severe 
functional defects (Osato et al., 1999; Preudhomme et al., 2000).  
1.9.2 C/EBPα   
The CCATT/enhancer binding protein alpha is a leucine-zipper transcription factor 
that plays a pivotal role in granulocyte development but also has an activity as a 
tumour suppressor in the haematopoietic system (Yamanaka et al., 1997; 
Yamanaka et al., 1997).  Aberrant activity of C/EBPα, which can develop either as a 
result of the action of fusion proteins (such as AML1/ETO) or from direct mutation at 
the C/EBPα locus, causes abnormal granulocytic outgrowth in 10-15% of AML-M1 
and M2 cases (Snaddon et al., 2003). 
1.9.3 PU.1  
Reflecting its important role as a master regulator of haematopoiesis, the disruption 
of PU.1 function often leads to leukaemia, in particular AML.  Experimentally, the 
graded reduction of PU.1 levels in mice results in myeloid leukaemia resembling 
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AML (Vangala et al., 2003; Dakic et al., 2007; Kastner and Chan, 2008).  
Furthermore, the oncogenic proteins RUNX1/ETO, Flt3/ITD and PML-RARα have 
been shown to suppress PU.1 expression in acute leukaemia, indicating a possible 
tumour suppressor role for PU.1 in myeloid cells (Dakic A, 2007 Vangala et al. 
2003). 
1.9.4 HoxA9  
Dysregulation of HoxA9 has been documented to be a dominant mechanism of 
leukaemic transformation in many cases of AML, and is often associated with poor 
prognosis.  The experimental enforced expression of HoxA9 leads to long-latency 
leukaemia, while the combined co-expression of HoxA9 and its partner protein 
Meis1 results in the rapid onset of AML, indicating that HoxA9 plays a central role in 
initiating leukaemogenesis by conferring growth advantage, but is itself not able to 
support the progression of leukaemia (Wang et al., 2006).  Moreover, Hox family 
members are associated with chromosomal translocations that result in the 
formation of the fusion gene NUP98/Hox (Mayotte et al., 2002) and are a direct 
target of MLL fusion genes.  Additionally, HoxA9 is strictly required for MLL/ENL-
induced leukaemogenesis (Zeisig et al., 2004). 
1.9.5 Meis1  
Meis1 is frequently up regulated in AML and ALL.  Furthermore, overexpression of 
Meis1 synergizes with HoxA9 and Hox fusion genes (eg NUP98/HoxA9) in 
enhancing leukaemogenesis in murine cell models (Mayotte et al., 2002).  Meis1 
and HoxA9 form either dimeric (Meis1-HoxA9) or trimeric (Meis1/HoxA9/Pbx1) 
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complexes, and it has been shown that Meis1 alone is not able to induce leukaemia.  
HoxA9 on the other hand is eventually able to induce leukaemia alone, but only after 
a long latency period.  Co-expression of both Meis1 and HoxA9 results in the rapid 
onset of AML, underlining the cooperative role of Meis1 in accelerating HoxA9-
induced leukaemia (Wang et al., 2006). 
1.9.6 c-myb  
The involvement of c-myb in leukaemia has been unclear in spite of its original 
identification as the transduced oncoprotein in the AMV and E26 avian acute 
leukaemia viruses (Frampton et al., 1996).  Increased c-myb expression is 
associated with several cases of myeloid and lymphoid leukaemia, although no 
evidence of mutation in the c-Myb coding sequence has been provided.  Recently, 
c-myb has been shown to be essential for leukaemogenesis in a BCR/ABL-induced 
chronic leukaemia model, in which a decreased level of c-myb reduced the 
clonogenicity of p210 BCR/ABL-transformed progenitors (Lidonnici et al., 2008).  
Furthermore, recent studies have identified a chromosomal translocation between 
the c-myb and T-cell receptor β genes and c-myb gene duplication in a 
heterogeneous subset of ALLs (Clappier et al., 2007).  To date, whether c-myb is 
directly involved in leukaemia or not is yet to be determined. 
1.10 Chromatin modifying enzymes 
1.10.1 MLL 
Chromosomal translocations involving the MLL gene are frequent in infant and adult 
AML (Ayton and Cleary, 2001).  Many MLL fusion partners have been described, 
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although only a few of them appear to be of clinical relevance in AML.  The most 
investigated MLL rearrangements are MLL-AF4 (t(4;11) (q21;q23)), MLL-AF9 
(t(9;11) (p22;q23)), and MLL-ENL (t(11;19) (p12;q23)).  The presence of these 
translocations is often associated with a particularly poor outcome (Schichman et 
al., 1994; Lochner et al., 1996).  Most of the MLL fusion proteins are associated with 
an altered transcriptional programme in which transcription of the two genes HoxA9 
and Meis1 is known to be causal for AML.  The mechanism of this transcriptional 
derepression is still unclear, though many fusion proteins recruit activating 
transcription factors or histone acetyltransferase activity to target promoter.  This 
idea is supported by the involvement of the MLL partner ENL as an RNA 
polymerase II elongation factor (Shilatifard et al., 1996).  Moreover, recent studies 
have described a phenomenon of epigenetic compensation in which the decreased 
H3K4 methyltransferase activity is balanced by the acquisition of H3K79 
methyltransferase activity, resulting therefore in a sustained and unique 
transcriptional programme (Krivtsov and Armstrong, 2007). 
1.10.2 MYST Family of acetyltransferases 
MYST proteins are part of a large family of histone acetyltransferase that serve as a 
co-activator for several haematopoietic transcription factors. Several family 
members are well known for their involvement in cellular transformation (Iwasaki et 
al., 2005). The monocytic leukaemia zinc-finger protein MOZ   in particular is 
involved in many chromosomal translocations generating the fusion proteins MOZ-
CBP, MOZ-p300, and MOZ-TIF2, which occur in 6% of AML-M4 and AML-M5 (Yang 
and Seto, 2007; Yang and Ullah, 2007). MOZ fusions involving the replacement of 
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the MOZ C-terminal region with CBP or p300, hence incorporating the 
acetyltransferase activity of the co-activator, result in an unusual hyperacetylated 
status of the chromatin and consequent aberrant patterns of gene expression 
(Kitabayashi et al., 1998). Another family member, the Tat-interactive protein TIP60 
has been associated with different types of cancer, although is involvement in 
leukaemia is still unclear. It has never been associated to any chromosomal 
translocation in leukaemias, however, altered TIP60 expression could comprise the 
transcriptional activity of C/EBPα, which normally functions as a tumor suppressor in 
many myeloid leukaemias (Bararia et al., 2008). 
1.11 Flt3 as a paradigm for normal and abnormal gene 
regulation in HSC and leukaemia 
1.11.1 The Flt3 receptor 
FMS-like tyrosine kinase 3 (Flt3), also known as foetal liver kinase-2 (Flk-2), stem 
cell kinase-1 (Stk-1) and CD135, is a membrane-bound receptor tyrosine kinase 
(RTK) expressed in immature haematopoietic cells (Rosnet et al., 1991; Rosnet et 
al., 1991).  Together with its ligand FL, Flt3 plays an important role in the normal 
development of stem cells and the immune system (Drexler, 1996; Rosnet et al., 
1996a; Rosnet et al., 1996b).  Flt3 is a member of the Type III RTK subfamily that 
includes the macrophage colony-stimulating factor receptor (c-Fms), stem cell factor 
(SCF) receptor (c-Kit) and the platelet-derived growth factor receptors α and β 
(PDGFRα/β).  Each of these cytokines and their receptors take part in the process 
of differentiation and proliferation of haematopoietic cells (Mathews and Vale, 1991). 
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The human flt3 gene located on chromosome 13 (13q12) is over 100kbp long and is 
composed of 24 exons encoding a 993 amino acid protein (Carow et al., 1995).  Flt3 
protein can be present as an unglycosylated form of 140KDa or a 160KDa 
membrane-bound protein that is glycosylated at the N-linked glycosylation site in the 
extracellular domain (Lyman et al, 1993; Carow et al, 1996).  Flt3 consists of five 
immunoglobulin-like extracellular domains, a transmembrane region, a cytoplasmic 
juxtamembrane (JM) domain, and two cytoplasmic kinase domains linked by a 
kinase-insert domain (Agnes et al., 1994) (Figure 1.7).  Flt3 binds its ligand FL 
inducing dimerization, autophosphorylation and the consequent phosphorylation of 
substrates involved in the initiation of signal transduction pathways that regulate the 
ability of stem cells to potentiate downstream multilineage expansion. 
1.11.2 Flt3 ligand (FL) 
The FL gene encodes a Type I transmembrane protein belonging to the family of 
cytokines that includes SCF and macrophage colony-stimulating factor (M-CSF) 
(Lyman et al., 1993; Hannum et al., 1994; Lyman et al., 1994).  The structure of FL 
consists of an amino-terminal signalling peptide, an extracellular domain that is 
responsible for the ligand activity, a spacer and a tether region that anchor the 
protein to the cell, a transmembrane domain and a cytoplasmic domain (Savvides et 
al., 2000).  FL mRNA is expressed in most haematopoietic and non-haematopoietic 
tissues, although the FL protein, either in soluble or membrane-bound form, is 
detectable only in T lymphocytes and stromal fibroblasts in the bone marrow (Lyman 
et al. 1993; Hannum et al. 1994).   
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Figure 1.7 Schematic representation of Flt3 receptor structure (from “FMS-like 
tyrosine kinase 3 in normal haematopoiesis and acute myeloid leukaemia” 
Parcells et al, 2006). This figure depicts the structure of the membrane-bound flt3 
receptor. The extracellular N-terminal Immunoglobulin-like domains, the 
transmembrane domain, the juxtamembrane domain and the C-terminal kinase 
domains are indicated. 
FL is not able to promote the proliferation of myeloid and lymphoid progenitors 
efficiently by itself, but experimental evidence indicates that FL is able to induce 
proliferation in the stem cell compartment in synergy with haematopoietic growth 
factors and cytokines, such as interleukin-3 (IL-3), granulocyte colony-stimulating 
factor (G-CSF), colony-stimulating factor-1 (CSF-1) and granulocyte macrophage 
colony-stimulating factor (GM-CSF) (Lyman, 1995; Ray et al., 1996; Ebihara et al., 
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1997)Strict regulation of the export of FL to the cell surface in essential to avoid 
hyperstimulation of primitive haematopoietic cells, which would otherwise initiate a 
leukaemic process (Wodnar-Filipowicz, 2003). 
1.11.3 Flt3 signalling 
Binding of FL to Flt3 initiates a downstream signalling cascade involving 
phosphorylation and activation of multiple cytoplasmic effector molecules on 
pathways connected with apoptosis, proliferation and differentiation (Lyman et al., 
1993; Hannum et al., 1994; Lyman et al., 1994).  Prior to the cloning of FL, studies 
on Flt3 signalling pathways were performed using a chimeric receptor consisting of 
the extracellular domain of the human c-Fms and transmembrane and cytoplasmic 
domains of Flt3 (Dosil et al., 1993).  Activation of the chimeric Fms-Flt3 protein in 
murine NIH3T3 fibroblast and in immature lymphoid BaF3 cells by stimulation with 
M-CSF resulted in a proliferative response independent of the presence of other 
cytokines or growth factors.  The response to stimulation involved the interaction 
with phospholipase Cγ1, Ras GTPase-activating protein (GAP) and Src family 
tyrosine kinases, or proteins that function as adaptors for other downstream 
effectors, like PI 3’-kinase (PI3K), signal transducer and activator of transcription 
protein 5 (STAT5), Nck and growth factor receptor-bound protein 2 (Grb2) (Dosil et 
al., 1993; Rottapel et al., 1994; Zhang et al., 2000).  The subsequent cloning of FL in 
1993 by Lyman and colleagues enabled confirmation of the observations obtained 
with the chimeric receptor.  Hence, binding of FL to Flt3 leads to triggering of the 
RAS and PI3K pathways and sustained cell proliferation and inhibition of apoptosis.  
The activity of PI3K is modulated by Flt3 through interaction with SH2-containing 
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proteins (SHCs), the proto-oncogene CBL and Grb2-binding protein (Gab2).  
Furthermore, Flt3-induced PI3K activation blocks apoptosis by phosphorylation of 
the Bcl-2 family protein Bad.  On the other hand, activation of Ras stimulates Raf, 
MAPK/Erk and STAT5 pathways, which result in the transcription of genes involved 
in cell proliferation (Zhang et al. 2000; Stirewalt et al 2003; Parcells et al, 2006) 
(Figure 1.8). 
1.11.4 Flt3 and haematopoiesis 
The murine flt3 cDNA was first isolated from foetal liver cells (Matthews et al., 1991) 
and subsequently the human homologue was cloned in 1994 (Rosnet et al., 1996a; 
(Rosnet et al.; 1996b).  As discussed above, the expression of the flt3 gene in the 
bone marrow is restricted to the multipotent progenitor population of the HSC 
compartment, phenotypically characterized as Lin-Sca-1+Kit+Flt3+ (Figure 1.9).  Flt3 
is highly expressed in early progenitor cells with lymphoid and myeloid potential and 
to a lesser extent in a subset of B-cells and in myeloid dendritic precursor cells 
(Adolfsson et al., 2001; Adolfsson et al., 2005).  Mackarehtschian and colleagues 
generated mice genetically engineered to lack the expression of functional Flt3 in 
1995; these developed as healthy adults with normal mature haematopoietic 
populations and normal peripheral blood counts but with specific deficiencies in 
primitive B lymphoid progenitors (Mackarehtschian et al., 1995).  Furthermore, bone 
marrow transplantation assays revealed a reduced ability of stem cells lacking Flt3 
to contribute to both B cells and myeloid cells, demonstrating an important role for 
Flt3 in the development of multipotent stem cells and B-cells (Mackarehtschian et 
al., 1995; McKenna et al., 2000).  Similarly, targeted disruption of FL resulted in a 
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significantly reduced number of B-cell progenitors, dendritic cells and NK cells in the 
bone marrow and lymphoid organs, the phenotype of these mice being partially 
reverted by the administration of FL (McKenna et al., 2000).  Moreover, transgenic 
mice engineered to over express FL developed leukaemia after a long latency, 
highlighting the importance of Flt3 and its ligand in normal haematopoietic 
development (Hawley et al., 1998).  It was also demonstrated that the activation of 
Flt3 by FL enhances in vitro and in vivo expansion of CD34+ progenitor cells, 
although the responses induced were dependent on the cell type and on synergy 
with other growth factors (Ray et al., 1996; Rusten et al., 1996; Veiby et al., 1996).  
Hence, stimulation of Flt3 alone was able to induce commitment of early 
heamatopoietic progenitors cells along the monocytic lineage, but resulted in a more 
robust response in combination with IL-3 and SCF, strongly enhancing the growth of 
both early precursors and granulocyte and monocyte progenitor cells, although no 
significant effect was observed on megakaryocytes and erythroid cells.  In addition, 
FL seems to play a key role during lymphoid differentiation, since it promotes B-cell 
commitment and stromal cell-independent expansion of pro-B cells when applied 
together with IL-7.  In addition, FL induces the growth of immature thymic progenitor 
cells in combination with IL-3, IL-6, IL-7 and the expansion, but not the 
differentiation, of NK cells in combination with IL-15 (Rusten et al. 1996).  
Maraskovsky and colleagues reported that mice treated in vivo with FL in 
combination with IL-4 showed a drastic development of dendritic cells in the bone 
marrow, spleen, thymus and peripheral blood (Maraskovsky et al., 2000).  All of 
these studies have underlined the important, but not unique, role of Flt3 and its 
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ligand in normal haematopoiesis and immune system development (Maraskovsky  
et al., 1996; Namikawa et al., 1999; Stirewalt and Radich, 2003). 
 
Figure 1.8 Signal transduction pathways downstream Flt3 receptor activation 
(adapted from “FMS-like tyrosine kinase 3 in normal haematopoiesis and 
acute myeloid leukaemia” Parcells et al, 2006). This figure shows the 
downstream signalling following Flt3 receptor activation. PI-3K: phosphatidylinositol 
3-kinase; STAT5: signal transducer and activator of transcription 5; C/EBPβ: CCAAT 
enhancer binding protein β; Grb2: growth factor receptor-bound 2; ERK: 
extracellular-signal regulated kinase; MAPK: mitogen-activated protein kinase.  
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Figure 1.9 Flt3 expression in the haematopoietic hierarchy. This figure indicates 
the expression of the Flt3 receptor in multipotent progenitor (MPP) cells, in pre-pro 
B-cells and dendritic cells. LT-HSC: long term haematopoietic stem cells; ST-HSC: 
short term haematopoietic stem cells; CMP: common myeloid progenitors: CLP: 
common lymphoid progenitors; GMP: granulocyte/macrophage progenitors; MEP: 
megakaryocyte/erythrocyte progenitors; Dendr: dendritic cells; Gran: granulocytes; 
Mono: monocytes; Meg: megakaryocytes; Eryth: erythrocytes; NK: natural killer 
cells. 
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1.11.5 Flt3 and leukaemia 
A high percentage of haematopoietic malignancies, including 70% to 100% of AML of 
all subtypes, B-precursor cell ALL, and a fraction of lymphoid blast crisis, are 
characterized by high level expression of the flt3 gene (reviewed by Gilliland and 
Griffin, 2002).  Quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
data revealed a remarkably high expression of flt3 mRNA in 33 of 33 B-lineage ALL 
and 11 of 12 AML cases compared to the normal bone marrow (Carow et al., 1996).  In 
addition, flt3 expression on leukaemic blasts was reported in 18 of 22 AMLs and 3 of 5 
ALL cases by Rosnet and colleagues.  Since self-renewal potential and growth factor-
independent proliferation are important features of leukaemogenesis, the involvement 
of flt3 in proliferation in the stem cell compartment underlines its importance in 
signalling and its oncogenic potential.  Moreover, Flt3 is the most commonly mutated 
protein in AML, either through an internal tandem duplication (ITD) (see below) or 
single point mutation (eg in the kinase domain).  In a clinical study performed by Nakao 
and colleagues, analysis of flt3 mRNA revealed the presence of elongated fragments 
of the JM domain encoded by exon 14 and 15 in 17% to 26% of AML cases (Nakao et 
al., 1996).  In all the patients with this mutation, analysis of the genomic DNA sequence 
showed an in-frame tandem duplicated sequence in the JM domain and occasionally 
the insertion of additional nucleotides.  The disruption of the JM domain, which 
negatively modulates kinase activity, results in the auto-activation of the receptor, 
although the molecular mechanisms supporting this process are yet to be fully clarified.  
Functional studies involving the Flt3-ITD demonstrated the constitutive activation of 
PI3K, Ras/MAPK and STAT5 downstream signalling pathways, implying an oncogenic 
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function through prevention of apoptosis and differentiation.  Of the eight different 
single point mutations defined, the most recurrent results in the substitution of tyrosine 
for aspartic acid at position 835 in the kinase domain; this mutation (termed Flt3-D835) 
is observed in 5% to 10% of cases (Kottaridis et al., 2001; Moreno et al., 2003; 
Scheijen et al., 2004).  Whether mutated or not, flt3 gene expression is up regulated in 
almost all the cases of AML. 
1.11.6 Flt3 gene regulation 
The mechanisms leading to up-regulation of flt3 gene transcription in the most 
mature component of the HSC compartment compared to persistent expression of 
the gene in leukaemias are largely undefined.  Recently, some evidence has 
emerged regarding how flt3 gene expression is regulated in AML cells.  This work 
has been performed using a cultured progenitor cell model in which Meis1 and 
HoxA9 transcription factor expression cooperates to induce myeloid progenitor 
expansion (Wanget al., 2006).  Cells transformed by Meis1/HoxA9 (but not HoxA9 
alone) constitutively express flt3 (Wang et al., 2005; Hess et al., 2006; Wang et al., 
2006).  Chromatin immunoprecipitation analysis revealed that HoxA9 was recruited 
to the proximal promoter and enhancer regions on the flt3 locus in progenitors 
expressing either HoxA9 alone or co-expressing Meis1 and HoxA9, whereas Meis1 
was recruited to the promoter and enhancer regions only in progenitors immortalized 
by Meis1/HoxA9 co-expression.  
Regulation of the flt3 gene has also been investigated in B cell development.  
Holmes and colleagues observed that in Pax5 null mice the sustained expression of 
flt3 was combined to the block of B-cell differentiation, suggesting that one possible 
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function of Pax5 was to repress flt3. In order to confirm this hypothesis, Pax5-/- pro-
B cells were transfected with a retroviral vector expressing the inducible Pax5 ER, 
and it was showed that the induction of Pax5 resulted in the repression of flt3. This 
was also confirmed to be a direct effect, as Pax5 was shown to in vivo interact with 
the flt3 promoter (Nutt et al., 1999; Holmes et al., 2006). Furthermore, work carried 
out in our laboratory (Garcia et al, 2009), has suggested that flt3 gene expression 
may be directly regulated by c-myb.  Hence, conditional deletion of the c-myb gene 
was found to result in a rapid down regulation of flt3 mRNA levels in the KSL 
compartment of HSCs.  The mechanism by which c-myb acts is yet to be fully 
clarified. 
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1.12 Aims of the project 
 
The main objective of this thesis was to examine and understand the regulation of 
the flt3 gene in normal and leukaemic haematopoietic stem cells. Here are listed 
some of the main questions/approaches, described in this thesis:  
• To phenotype HPC7 and FMH9 cells in terms of their morphology, gene 
expression, cell surface antigens and differentiation capacity, and validate 
them as cellular models for the study of haematopoietic and leukaemic stem 
cells. 
• To identify any cis-regulatory regions in the flt3 locus using DNAseI 
hypersensitive site (HSS) analysis, employing both a Southern blot analysis 
and a quantitative PCR approach in both cell lines and primary sorted cells. 
• To identify in vivo transcription factor binding in the vicinity of specific HSSs in 
the flt3 locus, performing chromatin immunoprecipitation (ChIP) assays with 
antibodies against specific transcription factors. 
• To identify by ChIP analysis epigenetic marks associated with transcriptional 
regulation of the flt3 gene, using antibodies that recognize particular histone 
modifications associated with either activation or repression of transcription. 
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Cell Culture 
The HSC-like line (HPC7) was kindly provided by Dr Leif Carlsson (Umea, Sweden).  
These cells were cultured at a density of 0.8-1.2*106/ml in Stem Pro medium 
(Invitrogen) supplemented with serum replacement (Gibco), 50 U/ml penicillin and 
50 µg/ml streptomycin (Gibco), 12 µM L-glutamine (Invitrogen) and 100 ng/ml of 
murine SCF (Peprotech) at 37°C in a 5% CO2 atmosphere. 
The LSC-like line (FMH9), derived from purified bone marrow progenitors co-
transformed with a retrovirus co-expressing the homeodomain transcription factors 
HoxA9 and Meis1, was kindly provided by Dr Robert Slany (Erlangen, Germany).  
These cells were grown at a density of 106/ml in RPMI (Sigma) supplemented with 
10% Fetal Bovine Serum (FBS, Autogen Bioclear), 50 U/ml penicillin and 50 µg/ml 
streptomycin (Gibco), 12 µM L-glutamine (Invitrogen), 5 ng/ml IL-3, 5 ng/ml IL-6 and 
5 ng/ml GM-CSF (Peprotech) at 37°C in 5% CO2. 
2.2 Cell analysis 
2.2.1 Surface marker expression analysis and cell sorting 
HPC7 and FMH9 cells were harvested, washed with phosphate buffered saline 
(PBS) and resuspended in 200 µl of RPMI supplemented with 10% FBS in a 96 V-
bottom well plate; centrifugation steps were carried out at 1100 rpm for 2 min at 4°C.  
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Non-specific binding was prevented by incubation with 5 µg/ml purified anti-mouse 
CD16/CD32 Fc-block antibody (FcγRII/III) (eBioscience) for 10 min on ice (except for 
staining for FcγRII/III analysis).  Primary antibodies conjugated to specific 
fluorochromes were used at a concentration of 10 µg/ml for 30 min on ice, followed 
by washing in PBS at 1000 rpm for 2 min at 4°C.  The primary antibodies used and 
the respective isotype controls are specified in Table 1.  Stained cells were 
resuspended in PBS/ 5% FBS and analysed on a FACSCalibur flow cytometer using 
CellQuest software (Becton Dickinson).  Live cells were selected by gating on 
forward scatter (FSC) / side scatter (SSC). 
For the sorting of primary cells bone marrow from five mice was flushed from tibias 
and femurs using 10 ml RPMI medium (Sigma) supplemented with 10% FBS in a 10 
ml syringe with a 23-gauge needle.  The bone marrow was subsequently filtered 
using a 70 µM cell strainer followed by centrifugation and washed in PBS.  The next 
step involved red cell lysis by resuspending the cells for 5 min at room temperature 
in ACK solution (0.15 M ammonium chloride, 1 mM potassium bicarbonate, pH 7.3 
disodium EDTA).  Cells were then centrifugated, resuspended in 300 µl of RPMI 
supplemented with 10% FBS and stained as described above.  Cell sorting was 
performed using a MoFlo high-speed cell sorter (Cytomation) and the cells collected 
into sterile tubes containing RPMI / 10% FBS and washed.  The antibodies used for 
the isolation of KSL and CMP cell are listed in Table 2 and Table 3, respectively.  
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2.2.2 Analysis of cell differentiation 
For the differentiation assay, 5x106 HPC7 cells, initially cultured as described above, 
were transferred to Stem Pro medium supplemented with a lower amount of SCF 
(20 ng/ml) and 200 ng/ml of recombinant human thrombopoietin (rhTPO) for 48 
hours.  Subsequently, the cells were cultured for 96 hours in the same conditions 
but in the presence of 200 ng/ml rhTPO alone to allow the cells to differentiate.  The 
next step consisted of the purification of mature megakaryocytes by isolation in a 0-
3% BSA gradient (4 ml 3% BSA / PBS followed by 4 ml 1.5% BSA / PBS and 4 ml of 
cell suspension in PBS layered successively in a 15 ml tube); cells sedimenting to 
the lower layer represent the mature fraction of megakaryocytes. 
In order to test the response of HPC7 to IL-3 stimulus, 5x106 cells were similarly 
cultured in Stem Pro medium supplemented with 5 ng/ml IL-3 for 96 hours at 37°C in 
5% CO2.  Subsequently, undifferentiated or differentiated cells were washed in PBS, 
loaded into cytospin funnels on microscope slides and centrifuged for 5 min at 400 
rpm.  The slides were then treated using the Diff-Quick protocol, which entails 
sequential staining by dipping the slides 5 times for 1 sec each in (i) 2 µg/ml Fast 
Green Methanol, (ii) 1.22 mg/ml Eosin G in phosphate buffer (pH 6.6) and (iii) 1.1 
mg/ml Thiazine Dye in phosphate buffer (pH6.6).  Excess liquid was drained on 
paper after each solution.  The slides were air-dried and covered by mounting 
medium and a cover slip.  
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2.2.3 Analysis of Cell DNA content  
The analysis of the DNA content was achieved using Propidium Iodide (PI) staining.  
For this purpose, 106 of both HPC7 and TPO-induced HPC7 cells were washed in 
PBS, resuspended in PBS supplemented with 1% NP-40, and PI added to a 
concentration of 0.5 µg/ml.  The cells were immediately analysed on a FACSCalibur 
flow cytometer using Cell Quest software (Becton-Dickinson).  Events were acquired 
on a logarithmic scale and dead cells were excluded by FSC / SSC gating. 
2.3 RNA analysis 
2.3.1 RNA extraction 
Total RNA was isolated using Qiagen RNeasy mini kit.  Cells were harvested by 
centrifugation for 5 min at 1100 rpm and then disrupted by addition of RLT buffer, 
followed by a vigorous shake.  One volume of 70% ethanol was added and the 
whole solution transferred into the appropriate RNeasy spin column in a 2 ml 
collection tube, and spun at 10000 rpm for 15 sec.  RW1 buffer was then added to 
the spin column, followed by washes with RPE buffer.  After each addition the tubes 
were centrifuge and the flow-through discarded.  Columns were eluted with RNase-
free water and spun at 13000 rpm for 2 min.  Removal of contaminating genomic 
DNA was achieved by treatment with RNase-free DNase I (Qiagen). 
2.3.2 cDNA synthesis 
5 µg of RNA was added to each reaction containing 5 mM dNTPs (Invitrogen) and 5 
µg/µl of oligoDT primers (Invitrogen) and incubated for 5 min at 65°C then placed on 
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ice for 2 min to cool down.  Subsequently, 10 nM DTT (Invitrogen), 1 U/ml 
RNaseOut inhibitor (invitrogen), 5X first strand buffer (Invitrogen) and 2 U/ml of 
SuperscriptIII reverse transcriptase (Invitrogen) were added to a final volume of 50 
µl.  Reverse transcription was then carried out for 1 hour at 50°C, followed by a 15 
min heat inactivation at 75°C. 
2.3.3 Semi-quantitative RT-PCR 
All oligonucleotide primers were designed using Primer Express software and 
obtained from MWG Biotech.  PCR reactions were performed in 50 µl of Ready Mix 
PCR Master Mix (Abgene) containing 200 mM of the gene-specific primers.  Each 
PCR program involved 40 cycles, each of which consisted of steps of 95°C for 30 
sec, X°C for 30 sec (annealing temperature varies based on the primers used) and 
72°C for 30 sec; an extra denaturation step was applied at the start of the program 
for 5 min at 95°C.  β-Actin was used as the normalisation control.  For each PCR 
reaction, time points were taken at intervals of 3 cycles to assess the linear phase of 
amplification.  PCR products were analysed by electrophoresis on 2% agarose gels.  
The primer sequences and respective annealing temperatures are listed in Table 4. 
2.4 DNAaseI Hypersensitive Site (HSS) analysis 
2.4.1 Southern blot 
To perform HSS mapping, 2x106 cells per point were harvested, washed twice with 
cold PBS and then resuspended in 1 ml of Digestion Buffer per point (15 mM Tris-
HCl pH 7.5, 15 mM NaCl, 60 mM KCl, 5 mM MgCl2, 200 mM Glucose, 0.5 mM 
EGTA, 0.1% NP40).  Cells were vortexed and then aliquoted in 15 ml tubes.  
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DNaseI (Roche) was diluted to 5 units per µl in DNaseI diluent (25 mM Tris-HCl pH 
7.5, 50% glycerol) and then added at increasing concentrations to each sample 
every 15 sec, as follows: 
 
0 unit 5 unit 10 unit 20 unit 40 unit 60 unit 
0 µl 1 µl 2 µl 4 µl 8 µl 12 µl 
 
Samples were incubated for 10 min at 37°C in a water bath, and then the DNaseI 
reaction was stopped by adding 330 µl of Stop Reaction Buffer (100 mM EDTA, 4% 
SDS).  Subsequently, 10 µl of RNaseA at a concentration of 10 mg/ml was added.  
After 1 hour of incubation at 37°C, 100 µg of proteinase K (15 mg/ml, Roche) was 
added, and the samples maintained in the water bath at 37°C overnight. Phenol / 
chloroform extraction was performed, followed by EtOH precipitation and 
resuspension of the pellet in an appropriate volume of water.  The DNA 
concentration of each sample was determined by quantifying the optical density at 
260nm on the Nanodrop (Nanodrop Technologies).  The ratio between absorbance 
at 260nm and 280nm was also measured as a measure of DNA purity.  
Subsequently, 10µg of DNA from each sample was digested with restriction 
endonucleases StuI (for the 5’ region) and BamHI (to investigate the intronic region) 
in a solution supplemented with 2 mM spermidine, 2.5 mM MgCl2, 100X BSA and 
water up to 50µl.  The reaction was carried out overnight at 37°C and then the 
samples were run on a 0.8% agarose gel in 1X TAE buffer at 50 mV overnight.  The 
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agarose gel was washed in 1l of Denaturing Solution (600 ml dH20, 300 ml 5M 
NaCl, 100 ml 5M NaOH) for 1 hour and then further washed with Neutralising 
Solution (400 ml dH2O, 300 ml 5M NaCl, 121.14g Trizma) for one extra hour.  The 
gel was then rinsed in 10X SSC buffer for 10min and transferred overnight to a 
nylon membrane using a transfer apparatus which consisted of the gel, on which the 
nylon membrane was placed, followed by 3 layers of Whatman paper and a box of 
paper towels to allow sufficient capillary transfer.  The day after, the transfer 
apparatus was dismantled and the nylon membrane was first quickly rinsed in 6X 
SSC and then placed to dry in the oven at 80°C for 2 hours.  To proceed to the 
hybridisation step, the nylon membrane was incubated for 2 hours at 60°C in pre-
warmed Church Buffer.  The probe was prepared and radiolabelled with [32P] dCTP 
using the Stratagene Prime-It II kit and incubated overnight on the membrane.  
Subsequently, the membrane was washed with 2X SSC / 0.1%SDS and then 0.1X 
SSC / 0.1%SDS, exposed to film or scanned on a phosphoimager. Probe 
sequences are provided in Table 5. 
2.4.2 Real Time PCR  
Real Time PCR was performed with Sybr Green (ABgene) with specific 
oligonucleotide primers designed using Primer Express software and obtained from 
MWG Biotech.  These primers were designed to generate products between 110 
and 220 bp and tested for the formation of primer dimers.  The primer efficiency was 
tested by serial dilution of both DNA and primer concentration.  40ng of DNA was 
amplified in 96 well plates in a total volume of 20 µl, using Absolute QPCR SYBR 
Green Mix (ABgene) and 200 mM of each primer pair.  Following an initial 15 min of 
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denaturation and activation step at 95°C, PCR cycles were performed at 95°C for 20 
sec, 56-64°C for 20 sec and 72°C for 20 sec, and repeated 40 times.  The MxPro 
software of the Stratagene Real Time PCR machine calculated the amplification 
efficiency and the Ct-value of each sample.  The primer sequences are listed in 
Table 6. 
2.5 Cross-linked chromatin immunoprecipitation 
X-ChIP experiments were performed following a modified version of the Abcam 
protocol (www.abcam.com/technical), the buffers compositions being the same 
unless specified.  2x107 cells were incubated in culture medium with 1% 
formaldehyde for 10 min at room temperature on a shaker.  Chromatin crosslinking 
was stopped by addition of glycine pH 7.5 at a final concentration of 0.125 M.  The 
cells were washed twice with cold PBS and resuspended in 1.5 ml of lysis buffer (50 
mM HEPES-KOH pH 7.5, 140 mM NaCl, 1 mM EDTA pH8, 1% Triton X-100, 0.1% 
sodium deoxycholate, 0.1% SDS, 5 mM sodium butyrate and protease inhibitors).  
The chromatin was sheared by 12 pulses of 2 min sonication using the VibraCell 
sonicator (Sonics & Material inc) with amplitude of 25 to obtain DNA fragments of 
300-600 bp in length.  After sonication, the chromatin preparation was centrifuged 
for 1 min at room temperature at 13000 rpm.  At this stage the supernatant was 
collected and stored at -70°C.  To test the DNA concentration and the efficiency of 
the sonication step, a 50 µl aliquot was precleared for one hour in dilution buffer with 
15 µl of Protein G Agarose and 15 µl of Protein A Agarose beads (Upstate Ltd) at 
4°C on a rotating wheel.  The chromatin was then subjected to reverse crosslinking 
and DNA extracted as described in the Abcam protocol.  The amount of DNA was 
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estimated by optical densitometry and the sonication efficiency was analysed on a 
1.5% agarose gel.  Typically, 20-25 µg of sonicated DNA and 8 µg of antibody were 
used for each immunoprecipitation.  
Specific antibodies or the relative IgG control (mouse, goat or rabbit) were incubated 
in dilution buffer (1% Triton X-100, 2 mM EDTA pH 8, 150 mM NaCl, 20 mM Tris-
HCl pH 8, 5 mM sodium butyrate and protease inhibitors) with 15 µl each of protein 
A and G agarose/salmon sperm, for 3 hours at 4°C on a rotating wheel. Meanwhile, 
the shared chromatin, diluted 10X in dilution buffer, was first precleared with 15 µl 
each of protein A and G agarose/salmon sperm DNA for 1 hour at 4°C on a rotating 
wheel.  After spinning 1 min at 3500 rpm, the precleared chromatin was incubated 
with 8 µg of normal IgG for 2 hours at 4°C on a rotating wheel and then incubated 
for another hour with protein A and G agarose/salmon sperm DNA.  Next, the 
precleared chromatin was added to the antibody-protein A/G agarose preconjugates 
and incubated overnight at 4°C on a rotating wheel. The next day, the 
immunoprecipitates were washed sequentially using wash buffers (basic buffer: 
0.1% SDS, 1% Triton X-100, 2 mM EDTA pH8, 20 mM Tris-HCl pH 8) containing 
increasing amounts of NaCl (500 mM, 600 mM and 750 mM).  Elution was 
performed for 1 hour at 65°C in 200 µl of Q2 elution buffer (20 mM Tris-HCl pH 8, 5 
mM EDTA pH8, 150 mM NaCl, 1% SDS, 5 mM sodium butyrate, 1 µg/ml RNAseA) 
and reverse cross-linking was achieved by addition of 1 µl of proteinase K (15 
mg/ml) followed by incubation at 65°C for 2 hours.  The immunoprecipitated DNA 
was extracted once with phenol-chloroform-isoamyl alcohol and ethanol precipitated 
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before analysis by quantitative PCR.  Table 7 and 8 provide details of antibodies 
used for epigenetic and transcription factor analysis. 
2.6 Downregulation by ShRNA and overexpression studies 
The genetic manipulation of c-Myb and C/EBPα expression levels was achieved by 
transfecting 10x106 cells from each cell line with pSiren-ShMyb (home made) and 
pGFP-V-RS-ShC/EBPα (Origene) respectively, or their corresponding non effective 
scrambled vectors. The plasmids used for the overexpression studies were 
pcDNA3-Myb and pCMV6-C/EBPα, which were compared to the empty control 
vectors. 
2.6.1 Cell transfections 
Transfections of ShRNA and expression vectors were performed using AMAXA 
Nucleofector kit (Lonza Technologies).  For this purpose 4 µg of each plasmid were 
resuspended in electroporator cuvettes in 100 µl of AMAXA L solution, together with 
1 µg of a GFP-expressing vector in order to assess the efficiency of the transfection 
by FACS analysis.  107 cells were washed twice with PBS, resuspended in the DNA 
solution and transfected with the AMAXA electroporator (program X-001).  
Immediately after transfection, cells were placed in warm RPMI medium (without 
serum or antibiotics) and incubated for 1 hour at 37°C 5% CO2.  Cells were then 
resuspended in their specific medium (Stem Pro medium for HPC7 and RPMI for 
FMH9) supplemented with serum and antibiotics, and incubated overnight at 37°C 
5% CO2. 
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2.6.3 Transfection efficiency and analysis 
The efficiency of transfection was evaluated by measurement of the proportion of 
GFP-expressing cells 24 hours after electroporation.  Cells were harvested, washed 
once with PBS and resuspended in 300 µl of medium.  Dead cells were excluded by 
gating.  Dot plots for the analysis of GFP expression are represented in Figure 2.1. 
Total RNA from GFP sorted cells was extracted and corresponding cDNA was 
analysed by Q-PCR to assess the expression levels of c-Myb, C/EBPα and flt3. 
GAPDH was used as housekeeping control. The primer sequences used for this 
analysis are listed in table 9. 
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Figure 2.1 Analysis of Flow Cytometry in ShRNA transfected cells and GFP 
sorting. Two-dimensional dot plot representing live cells gated on forward scatter 
(FSC) versus side scatter (SSC) in both HPC-7 (top panel) and FMH9 (bottom 
panel).  The dot plots on the right represent the percentage of GFP positive cells 
after transfection.  The fluorescence from GFP positive cells was detected in the 
FITC channel. 
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Table 1: Monoclonal antibodies used for flow cytometric analysis of surface 
antigens 
 
Specificity Conjugate Isotype Supplier 
CD117 (c-kit) FITC Rat IgG2b eBioscience 
CD34 APC Rat IgG2b BD Pharmigen 
Sca1 APC Rat IgG2a eBioscience 
Gr-1 FITC Rat IgG2a eBioscience 
CD11b (Mac-1) FITC Rat IgG2b eBioscience 
CD135 (Flt3) PE Rat IgG2b eBioscience 
CD16/32(Fc !RII/III)  Rat IgG2b eBioscience 
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Table 2: Monoclonal antibodies used for KSL cell sorting 
 
Specificity Conjugate Supplier 
CD5 FITC eBioscience 
CD8a FITC eBioscience 
CD11b (Mac-1) FITC eBioscience 
Gr-1 FITC eBioscience 
B220 FITC eBioscience 
Ter119 FITC eBioscience 
CD117 (c-Kit) Cy5 eBioscience 
Sca-1 APC eBioscience 
CD135 (Flt3) PE eBioscience 
CD16/32(Fc !RII/III)  eBioscience 
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Table 3: Monoclonal antibodies used for CMP sorting 
 
Specificity Conjugate Supplier 
CD5 FITC eBioscience 
CD8a FITC eBioscience 
CD11b (Mac-1) FITC eBioscience 
Gr-1 FITC eBioscience 
B220 FITC eBioscience 
Ter119 FITC eBioscience 
CD117 (c-Kit) Cy5 eBioscience 
Sca-1 APC eBioscience 
CD34 Biotin (*) eBioscience 
CD16/32(Fc !RII/III) PE eBioscience 
(*) Required a Streptavidin APC-Cy7 conjugated secondary antibody  
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Table 4: RT-PCR primer sequences 
 
β-Actin  5'-ctttgcagctccttcgttgc-3' GATA3 5'-cacgatccagcacagaag-3' 
  5'-tctgacccattcccaccatca-3'   5'-atagtcaggggtctgttaat-3' 
Ets1 5'-cagtcatccttcaacagcc-3' c-Myb 5'-ctcccacaccattcaaac-3' 
  5'-ctcttgaaaggtctcagcag-3'   5'-caaaatcaggctcttctctc-3' 
Ets2 5'-gctcaacaccgtcaatgtc-3' c-kit 5'-gctcataaatggcatgctcc-3' 
  5'-tttttcctcttcccccac-3'   5'-aagttgcgtcgggtctatgt-3' 
PU.1 5'-tggaagggttttccctcacc-3' Flt3 5'-aagttcagttacacccgcc-3' 
  5'-tgctgtccttcatgtcgccg-3'   5'-acatcgcttcttctgcctc-3' 
Fli1 5'-agccagatccttatcagatcc-3' Meis1 5'-gggttcctcggtcaatgacg-3' 
  5'-cagtaaagtgagagctggaac-3'   5'-cgaatctgtttggcgaacacc-3' 
Elf2 5'-agccacgaaccaatgaaaaag-3' HoxA9 5'-ctccgaaaacaatgccgaga-3' 
  5'-gctctggagcagttcagaggag-3'   5'-tgcctttcggtgaggttga-3' 
Elk4 5'-aacagattgatccctccacgtc-3' HoxB4 5'-cttggatgcgcaaagttca-3' 
  5'-cagtctccctcaatcctggcta-3'   5'-acttcatgcgccgattct-3' 
Tel1 5'-taactctcaccctctcccttc-3' CBP 5'-aggcaggaggcatgacca-3' 
 5'-ccccagtaagagtgatgagcag-3'   5'-tcccactgatgtttgcaactg-3' 
GATA1 5'-cccttgtgaggccagaga-3' MLL1 5'-ggccaagcactgtcggaatt-3' 
  5'-acctgatggagcttgaaatag-3'   5'-gcggatttcagcttgacct-3' 
GATA2 5'-tgggctctaccacaagatga-3' p300 5'-tcatgaacggttccattgga-3' 
  5'-gtgacttctcttgcatgcac-3'   5'-ctgaatttggagaccaaggcc-3' 
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Table 5: Primer sequences for probes used for Southern Blot approach 
 
StuI  5’-gaggagctaagagcaatggtgg-3’ 5’-aactttatggtcaaacctcccct-3’ 676bp 
BamHI 5’-ctcaccacacttggcaaaatcac-3’ 5’-agacctcagaaatgcatgctagg-3’ 550bp 
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Table 6: Real time PCR primer sequences 
 
-3503  5'-cccctgtttgtgtggttctgg-3' -2584 5'-caaaacaagtattcaacaccatgcc-3' 
  5'-tttttcttccattctgtggattacc-3'   5'-cacttactgcttcttggctcagg-3' 
-2496 5'-acttactgcttcttggctcaggtt-3' -2404 5'-atgggagtttgtaacttcggg-3' 
  5'-ccctgtaataacgactctgaggg-3'   5'-tctccaactagctcataacccaa-3' 
-2261 5'-cctgtaataacgactctgagggtaat-3' -1641 5'-tcttaggcgttggtgtcttctctt-3' 
  5'-taagagattctatcggagctggg-3'   5'-tctgagaactgtcctgggatg-3' 
-1344 5'-gagcaccacatgctcggaga-3' -1059 5'-tcactgtggtgtgcaggaatg -3' 
  5'-aggtagctgtgtgggaattgc-3'   5'-ccatgtcatttccacagtgg-3' 
-953 5'-gcccatgtcattttccacagt-3' -778 5'-gacacgagagatggagcgata-3' 
  5'-tgtgcttgtatgctctcaggg-3'   5'-cctgtgctttcaatattcagctt-3' 
-426 5'-tcagtccacaatgcacatctacc-3' -258 5'-acggagtccaggcaacttccc-3' 
  5'-aagaggtctgtgtgtcacca-3'   5'-cacgtgggatcggctgcag-3' 
-152 5'-cagactgcgccagttca-3' -72 5'-accagtccgagggaatctgtgg-3' 
  5'-aatctgtggtcagtgacgcg-3'   5'-ccggcggcctggctacc-3' 
+447 5'-aaactaatgggaaaactgcg -3' +599 5'-cccctctccatacttttcttatt-3' 
  5'-agtggctagttactttggaaatact-3'   5'-agaagcatagctgtgattgaaa-3' 
+693 5'-gcatagctgtgattgaaaatactaac-3' +6970 5'-tttggtttaacgtactgcatagct-3' 
  5'-gaagacaagggggttgga-3'   5'-gaggtgccttgttttttgtcg-3' 
+7263 5'-gagacagggtctctcgtgagc-3' +7559 5'attgcataagatcctaaaagaggaac-3' 
  5'-caagtcacggacggttgttaa-3'   5'-ggagccaagaatccgctatag -3' 
+7614 5'-tattatgttgattgggagccaaga-3' +7768 5'-ggatcttgtcatttttttctctcaaat-3' 
  5'-aggtacacactaaattctgtcttcaaa-3'   5'-aggcttcccagtgctacttattc -3' 
+7799 5'-tggctttgcactgaagtttct-3'   
  5'-cagaaagggagacagagtctga-3'    
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Table 7: Antibodies used for epigenetic studies 
 
Specificity Isotype Supplier 
H3K4me3 Rabbit IgG Laura O’Neill 
H3K9ac Rabbit IgG Laura O’Neill 
H3K9me2 Rabbit IgG Laura O’Neill 
H4K8ac Rabbit IgG Laura O’Neill 
H3K79me3 Rabbit IgG Laura O’Neill 
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Table 8: Antibodies used for transcription factor ChIP 
 
Specificity Isotype Supplier 
HoxA9 Goat IgG Santa Cruz 
Meis1 Goat IgG Santa Cruz 
Pbx1 Rabbit IgG Santa Cruz 
Pbx2 Rabbit IgG Santa Cruz 
c-Myb Rabbit IgG Santa Cruz 
PU.1 Rabbit IgG Santa Cruz 
GATA-1 Rabbit IgG Santa Cruz 
GATA-2 Rabbit IgG Santa Cruz 
Sox2 Rabbit IgG Upstate Ltd 
C/EBPα Rabbit IgG Santa Cruz 
RUNX1 Goat IgG Santa Cruz 
MLL1 Mouse IgG Upstate Ltd 
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Table 9: Primers used for genetic manipulation studies 
 
GAPDH  5'-aactttggcattgtggaagg-3' 5'-acacattgggggtaggaaca-3' 
c-Myb 5'-ggagaggtggcacaaccatttg-3' 5'-tggctggctttggaaggctg-3' 
C/EBPα 5'-tggacaagaacagcaacgac-3' 5'-tcactgaactccagcac-3' 
 flt3 5'-cgcgaatgcaccaagctgt-3' 5'-ggtcctgtttgtggagtaggt-3' 
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CHAPTER 3: CHARACTERIZATION OF THE 
MODEL CELL SYSTEMS USED IN THIS STUDY 
 
3.1 Introduction 
The study of haematopoietic stem cells begun in the 60s when Till and McCulloch 
reported that the injection of bone marrow cells into irradiated hosts resulted in the 
formation of spleen colonies (Till and McCulloch, 1961), and was followed by the 
discovery by Metcalf and Bradley that bone marrow cells were able to give rise to 
heterogeneous colonies in semi-solid medium (Bradley and Metcalf, 1966).  
However, the existence of long-lived stem cells in the bone marrow was deduced 
only 20 years after in subsequent experiments involving clonal tracking of serial 
transplantation, performed independently by Dick (Dick et al, 1985) and Leminschka 
(Lemischka et al, 1986).  Since then, many efforts have converged in the generation 
of experimental models that suitably mimic haematopoiesis, in order to define the 
molecular mechanism governing the self-renewal process and to understand and 
describe how the determination of different cell lineages takes place (Ceredig et al., 
2009).  
The last two decades have seen a marked improvement in the ability to isolate and 
purify HSCs and a growing interest in the clinical application that these cells have, 
leading to the establishment of several culture systems for the in vitro expansion of 
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HSCs, although these systems have had only modest success due to the lack of 
knowledge about the processes governing HSC self-renewal (Domen and 
Weissman, 1999).  As an alternative, several research groups have established 
immortalized multipotent stem cell lines.  In 1980 Greenberger and coworkers 
reported that the infection of cultured bone marrow cells with spleen focus-forming 
virus resulted in the generation of an IL3-dependent multipotential haematopoietic 
cell line, named B6SUtA.  Colony-forming and differentiation assays demonstrated 
the capacity of B6SUtA cells to differentiate along the neutrophil-granulocyte, 
basophil-mast cell and erythroid lineages following specific stimulus (Greenberger et 
al., 1983; Greenberger et al., 1983).  The commonly used haematopoietic cell line, 
FDCP-mix, was established in liquid culture from bone marrow.  The growth of these 
cells requires constant supply of IL-3, as demonstrated by their rapid death after the 
removal of the cytokine.  Moreover, FDCP-mix cultured in a low concentration of IL-
3 respond to stimulation with GM-CSF and Epo by differentiating into myeloid and 
erythroid cells, respectively (Spooncer et al., 1984; Spooncer and Dexter, 1984).  
Tsai and colleagues established an SCF-dependent HSC-like line, EML, by infection 
of bone marrow cells with a retroviral vector harbouring a dominant-negative retinoic 
acid receptor.  The EML cell line exhibits the ability to generate B-cell progenitors 
and erythroblasts in response to IL-7 and Epo, respectively (Tsai et al., 1994; Tsai et 
al., 1994).  In spite of their ability to give rise to multilineage differentiation, these cell 
lines have only a modest repopulation potential in transplantation assays (Pinto do 
et al., 1998; Pinto do et al., 2002).  One cell line, termed HSCN1, which was 
established by Varnum-Finney et al through retroviral-mediated insertion of the 
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Notch1 intracellular domain into primitive mouse bone marrow cells, was reported to 
give rise to functional cells in vivo when cultured in the presence SCF, IL-6, FL and 
IL-11, although the mechanism leading to the immortalization was unclear (Varnum-
Finney et al., 2000). 
As with research of HSCs, the study of acute myeloid leukaemia has been impeded 
by the lack of suitable cellular models. This is partly due to the large diversity of AML 
subtypes, but also when considering the use of murine cellular models it is not 
entirely clear how closely mouse AML-like phenotypes parallel the corresponding 
human disease subtypes (Yin et al., 2006).  Since the emergence of the concept of 
“leukaemia initiating cell” (see Section 1.6), several murine AML-like cell lines have 
been generated, and they have proved useful in the study of how the modulation of 
transcriptional programmes or the aberration of signalling pathways can ultimately 
lead to leukaemia.  For example, the WEHI-3 myelomonocytic leukeaemia cell line, 
originally generated in BALB/c mice by Ralph and colleagues in 1977, has been 
used to test the cytotoxicity and growth inhibitory effects of macrophage activators 
on monocytic leukaemia (Ralph et al., 1977; Ralph and Nakoinz, 1977).  Similarly, 
the commonly used myeloblastic leukaemia cell line, M1, was established by 
Ichikawa in 1969 from a leukaemia spontaneously arising in the SL mouse strain.  
M1 cells have been used to study growth arrest and apoptosis of mature cells 
following IL-6 treatment and can be induced to commit towards mature 
macrophages in the presence of GM-CSF (Ichikawa, 1969; Kawashima et al., 2001).  
All the cell lines described above possessed several features of HSC-like (first part) 
and AML-like cells (last part). However none of these cells lines could have been of 
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interest for my work, since the choice of the cell models was dictated by the 
expression of flt3. This chapter is focussed on the characterization, in terms of 
surface antigen expression, morphology, differentiation capacity and gene 
expression, of the cell system used to study the regulation of flt3 gene expression in 
HSC-like and AML-like cells. Ultimately this chapter is also providing a detailed 
description of the strategy adopted for sorting the primary cells used to confirm 
some of the data obtained in cell lines.  
3.2 HPC7: A model for murine HSCs 
The HPC7 line was generated from haematopoietic stem cells obtained by 
differentiation of ES cells that had been transduced with a retrovirus expressing the 
LIM-homeodomain protein Lhx2.  ES cells infected with the murine stem cell virus 
(MSCV) retroviral vector containing the mouse LX2 cDNA were expanded in culture 
in the presence of leukaemia inhibitory factor (LIF); cells from individual colonies 
being grown in media supplemented with Epo, SCF and IL-3.  In the absence of 
these cytokines the cells died within a few days, whereas growth in media 
supplemented with Epo and IL-3 resulted in a few rounds of division followed by 
differentiation towards erythrocytes and macrophage-like cells, respectively.  In 
contrast, growth in the presence of SCF was sufficient to allow expansion for more 
than seven months, all of the cells maintaining a primitive blast-like morphology 
(Pinto do et al., 1998; Pinto do et al., 2002).  In order to assess the extent to which 
HPC7 cells display the characteristics of HSCs, I analysed their surface antigen 
expression, differentiation capacity and HSC-related transcription factor expression.  
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3.2.1 Surface antigen expression  
HPC7 cells grown in presence of SCF were tested by immunofluorescence staining 
and flow cytometry using antibodies against the mature blood lineage markers Gr-1 
and Mac-1, and the stem cell related antigens Sca-1, c-Kit, CD34 and Flt3.  This 
analysis revealed the expression of CD34, c-Kit and Sca-1, but the cells were 
negative for both Mac-1 and Gr-1, consistent with an immature stem cell-like 
phenotype.  Flt3 expression was barely detectable on the majority of cells, although 
a small subpopulation (1.5%) exhibited Flt3 staining, possibly reflecting a degree of 
spontaneous differentiation (Figure 3.1). 
3.2.2 Differentiation capacity 
HPC7 cells exhibit indefinite self-renewal capacity in culture in the presence of SCF.  
Morphological analysis following Giemsa staining indicated that the cells cultured in 
SCF remained undifferentiated and blast-like (Figure 3.2A).  The ability of HPC7 to 
differentiate towards myelomonocytic or megakaryocytic lineages was tested by 
culturing them in the presence of IL-3 and TPO, respectively.  Cells were cultured 
for 48 hours in the presence of SCF (10 ng/ml) plus rhTPO (200 ng/ml) or IL-3 (5 
ng/ml), and subsequently were deprived of SCF and cultured for 96 hours in rhTPO 
or IL-3.  TPO-induced cells were subjected to BSA fractionation in order to 
concentrate mature megakaryocytes (as described in Materials and Methods).  
Phenotypic and morphological analysis showed that HPC7 cells were able to 
differentiate into mature myelomonocytic cells in response to IL-3 or into mature 
megakaryocytes in response to TPO (Figure 3.2A).  Moreover, analysis of the DNA 
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content of the undifferentiated versus mature megakaryocytes revealed a level of 
ploidy of 64n, consistent with a fully mature megakaryocytic phenotype (Figure 
3.2B). 
 
Figure 3.1 Phenotypic characterization of HPC7.  The surface antigen phenotype 
of the HSC-like HPC7 cell line was assessed by immunofluorescence / flow 
cytometry using a set of labelled antibodies against stem-cell related antigens (c-Kit, 
Sca-1, CD34 and Flt3) and lineage specific markers (Gr-1, CD11b) together with 
isotype matched controls (indicated in each plot by the filled histogram).  The green 
histogram represents the staining of each single antibody, as indicated below each 
plot; the positivity for each staining is determined by the shift of mean fluorescence 
compared to the control staining with the corresponding isotype control. This figure 
is representative of three indipendent experiments.                        . 
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Figure 3.2 Morphological analysis of differentiation. (A) The HPC7 differentiation 
assay was performed for 96 hours by culturing the cells in the presence of IL-3 or 
TPO.  Subsequently, cytospins and Diffquick stainings were performed on both 
HPC7 cells and their differentiated derivatives. The results demonstrate that HPC7 
cells can be maintained undifferentiated in culture or can be induced to differentiate 
into megakaryocytes and mixed myelomonocytes.  (B) The level of ploidy of TPO-
treated cells was assessed by quantification of the DNA content in the cell using 
propidium iodide staining in combination with flow cytometric analysis. This figure 
represents the typical result obtained in three independent experiments. 
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3.2.3 RNA expression  
In addition to the morphological analysis of HPC7 and the differentiated derivatives, 
I assessed the pattern of expression of a selected group of HSC- and lineage-
associated genes by semi-quantitative RT-PCR.  As expected for an HSC-like 
phenotype, undifferentiated HPC7 expressed high levels of PU.1, Elf-2, GATA-1 and 
GATA-2, but low levels of Ets-1 and Ets-2 (Swiers et al.; 2006).  Differentiation in the 
presence of TPO led to changes in this pattern of expression, in that the levels of 
Ets-1, Ets-2, PU.1 and GATA-2 RNAs decreased while the expression of Fli-1 and 
GATA-1 increased (Figure 3.3). 
Taken together, these data support the idea that the HPC7 cell line represents a 
good model of haematopoietic stem cells. 
3.3 FMH9: A model of Flt3+ AML 
The FMH9 cell line was generated by infection of purified Sca+/Lin- bone marrow 
progenitors with retroviruses encoding the homeodomain transcription factors Meis-
1 and HoxA9 (Kroon et al., 1998; Wang et al., 2006; Hess et al.; 2006).  For this 
purpose, HoxA9 and Meis1 cDNAs where cloned downstream of the LTR (long 
terminal repeat) region in the MSCVneo and MSCVpuro vectors, respectively.  Bone 
marrow cells infected with the two viruses, either alone or in combination, were 
grown in the presence of neomycin (HoxA9MSCVneo) and puromycin 
(Meis1aMSCVpuro) in order to test the drug-resistant proliferative capacity.  The 
immortalized cells obtained were then transplanted into syngeneic recipients (Wang 
et al.; 2006) 
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Figure 3.3 RNA expression.  The gene expression of undifferentiated versus TPO-
treated HPC7 cells was investigated by semi-quantitative RT-PCR.  The genes 
analysed are indicated and primers sequences are provided in Material and 
Methods (Table 4).  Each PCR reaction shown is represented by three samples 
starting at cycle 26, with three cycles intervals.  The analysis of PCR products on 
ethidium-bromide-stained agarose gels revealed a distinct pattern of Ets and GATA 
factor RNA expression, distinguishing HPC7 stem cells from their differentiated 
derivatives.  cDNA was normalized against β-Actin. This figure is representative of 
three indipendent experiments. 
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Only one out of nine recipients transplanted with HoxA9 immortalized progenitors 
developed leukaemia after a long latency (220 days) (Wang et al.; 2005).  In 
contrast, all of the recipients of HoxA9/Meis1 immortalized cells developed 
leukaemia within 50 days.  The cells transformed by HoxA9 and Meis1 possessed 
the characteristics of leukaemic blasts, that is, a high proliferative potential and 
blocked differentiation.  Interestingly, the HoxA9/Meis1 transformed cells (FMH9) 
exhibited expression of Flt3, making them a potentially suitable model to investigate 
the deregulation of flt3 gene expression in the context of AML.  To further 
characterise FMH9 cells and compare them to the HSC-like HPC7 cells, I performed 
a similar analysis of surface antigens, differentiation capacity and transcription 
factors expression.  
3.3.1 Surface antigen expression  
FMH9 cells were stained for lineage-specific markers and stem cell-related antigens, 
and analysed by flow cytometry. This analysis showed positive staining for c-Kit and 
Sca-1, but an absence of the expression of CD34.  The cells also showed high 
levels of expression of the lineage markers Gr-1 and Mac-1, indicative of a 
differentiation status roughly equivalent to a myelomonocytic progenitor.  Most 
interestingly, the FMH9 cells were positive for Flt3, in accordance with their AML-like 
phenotype (Figure 3.4). 
3.3.2 Differentiation capacity  
Like HPC7 cells, FMH9 cells exhibit the ability to self-renew indefinitely in culture, 
remaining undifferentiated after multiple passages.  Unlike HPC7 cells, it was 
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impossible to demonstrate any further maturation capacity of FMH9 cells in 
response to cytokines (Figure 3.5A), confirming a differentiation block at a 
myelomonocytic-like stage. 
3.3.3 RNA expression  
RT-PCR analysis was performed in order to determine the pattern of expression of 
specific transcriptional regulators.  Compared to HPC7 cells, FMH9 exhibited similar 
expression of Ets-1, Ets-2 and Fli-1, but a lower level of PU.1 and Elf-2 RNAs and a 
complete lack of expression of the GATA factors (Figure 3.5B).  
Taken together, these data suggest that FMH9 cells are more mature compared to 
HPC7, being blocked at the stage of a myelomonocytic progenitor. 
3.4. Sorted Primary HSCs 
As described in the Introduction (Section 1.11.4), flt3 gene expression is linked to 
the stage of maturation of HSCs within the KSL compartment.  In order to validate 
findings in primary cells and to be able to compare flt3 regulation in long- and short-
term repopulating cells and MPPs, a standard sorting strategy was adopted in order 
to purify the Flt3- and the Flt3+ fraction of the HSC KSL compartment.  For each 
experiment, bone marrow cells were extracted from 5 mice and then stained using a 
cocktail of antibodies against lineage committed markers (Lin: B220, Ter119, CD5, 
CD8a, Gr-1 and Mac-1), combined with antibodies against the stem cell related 
antigens c-Kit, Sca-1 and Flt3.  Cells negative for the lineage markers (Lin-) were 
gated, followed by the selection of cells double-positive for Sca-1 and c-Kit (i.e. KSL 
cells).   
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Figure 3.4 Phenotypic characterization of FMH9.  FMH9 cells were stained with 
labelled antibodies against stem cell-related antigens (c-Kit, Sca-1, CD34 and Flt3) 
and lineage specific markers (Gr-1, CD11b), and analysed by flow cytometry.  The 
filled histogram in each plot represent the matching isotype control while the line 
histogram indicates the staining obtained with each of the antibodies used.  FMH9 
cells express specific myelomonocytic markers Gr-1 and Mac-1, and show positive 
staining for c-Kit, Sca-1and Flt3 but not CD34. The positivity for each staining is 
determined by the shift of mean fluorescence compared to the control staining with 
the corresponding isotype control. This figure is representative of four indipendent 
experiments. 
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Figure 3.5 FMH9 differentiation and RNA expression analysis.   (A) Diffquick 
staining of a cytospin prepared from FMH9 cells was carried out in order to verify the 
cell morphology.  These cells were grown in RPMI supplemented with 10% of FBS, 
5 ng/ml IL-3, 5 ng/ml IL-6, 5 ng/ml GM-CSF and 50ng/ml of SCF (described in 
Material and Methods, section 2.1). (B) A comparison of gene expression in 
undifferentiated HPC7 and FMH9 cells performed by semi-quantitative RT-PCR.  
The genes analysed are indicated and primers sequences are described in 
Materials and Methods (Table 4).  The analysis of PCR products at cycles 29 and 32 
was performed on ethidium-bromide-stained agarose gels.  cDNA was normalized 
against β-Actin as a control. This figure represents the typical result obtained in 
three independent experiments. 
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Total KSL cells were then further fractioned, based on the expression of the Flt3 
antigen; KSL Flt3+ cells, which represent the MPP population, and KSL Flt3-, which 
consist of LT- and ST-HSCs (Pohlmann et al.; 2001) (Figure 3.6).  The number of 
purified cells obtained after sorting were roughly 2000 for KSL Flt3- and 3500 to 
4500 for KSL Flt3+. 
3.5. Sorted primary committed progenitors 
I adopted a second sorting strategy to obtain a population of cells with a higher 
degree of maturation relative to KSL cells, allowing comparison of the regulation of 
flt3 expression in cells that do not express flt3 yet (KSL Flt3-), cells expressing flt3 
(KSL Flt3+) and cells that have lost its expression (committed progenitors).  As for 
KSL isolation, bone marrow cells were stained using the Lin cocktail of antibodies 
combined with antibodies against the stem cell-related antigens c-Kit and Sca-1.  In 
addition, antibodies against CD34 and CD16/32 were included.  After the selection 
of Lin- cells, cells positive for c-Kit and negative for Sca-1 expression were gated 
and divided into three populations on the basis of their expression of CD34 and 
CD16/32: (i) CD34- CD16/32- (MEPs); (ii) CD34+ CD16/32+ (GMPs); and (iii) CD34- 
CD16/32+ (CMPs) (Akashi et al.; 2001) (Figure 3.7).  The number of cells obtained 
was roughly 3000, 3500 and 2000 for MEPs, GMPs and CMPs, respectively. 
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Figure 3.6 KSL sorting strategy. Total bone marrow cells were flushed from the 
tibias and femurs of five wild type mice.  Following red cell lysis, the cell preparation 
was filtered to avoid cell clotting and fluorescently labelled with a cockatil of 
antibodies against lineage-committed markers (B220, CD5, CD8a, CD11b, GR-1 
and Ter119) and stem cell-specific antigens Sca-1, c-Kit and Flt3.  (A) Two-
dimensional dot plot representing live cells (R1 region) gated on forward scatter 
(FSC) versus side scatter (SSC).  (B) The two-dimensional dot plot represents the 
lineage negative fraction (R2 region) of the total bone marrow.  (C) A two-
dimensional plot representing the expression of stem cell-related antigens Sca-1 
and c-Kit on the total lineage negative cells gated in panel B.  Cells gated in region 
R3 represent the total KSL fraction of the bone marrow. (D) KSL cells were further 
analysed for the expression of Flt3.  The Flt3+ cells in R4 region correspond to the 
multipotent progenitors (MPP) and Flt3- in R5 region group together both long-term 
(LT-HSC) and short-term stem cells (ST-HSC). This figure represents the typical 
result obtained in five independent experiments. 
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Figure 3.7. CMP/GMP/MEP sorting strategy.  Total bone marrow cells were 
extracted from tibias and femurs of wild type mice and red cells were selectively 
lysed.  The cell preparation was filtered to avoid cell clotting and fluorescently 
labelled with a cockatil of antibodies against lineage-committed markers (B220, 
CD5, CD8a, CD11b, GR-1 and Ter119) and stem cell-specific antigens Sca-1, c-Kit, 
CD34 and CD16/32.  (A) Two-dimensional dot plot representing live cells (R1 
region) gated on forward scatter (FSC) versus side scatter (SSC).  (B) The two-
dimensional dot plot respresents the lineage negative fraction (R2) of the total bone 
marrow.  (C) Panel C shows the two-dimensional plot representing a cell population, 
of the total lineage negative cells gated in panel B, that shows positive staining for c-
Kit and negative for Sca1.  (D) Cells gated in the R3 region were further fractioned 
on the basis of the expression of CD34 and CD16/32.  The indicated regions 
correspond to the Granulocyte-Macrophage Progenitors (R4), Megakaryocyte / 
Erythrocyte Progenitors (R5) and Common Myeloid Progenitors (R6). This figure 
represents the typical result obtained in three independent experiments. 
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3.6. Discussion 
The principal objective of this chapter is to show that the cell systems used in this 
thesis are an appropriate representation of HSCs and AML cells and therefore 
suitable for the investigation of the regulation of the flt3 gene presented in the next 
chapter. The choice of the cell systems was dictated by the need for cell lines that 
both possess the typical characteristics of HSCs and AML and express flt3.  
For this study I made use of an HSC-like line, HPC7, and an AML-like line, FMH9. In 
order to characterize these two cell lines, I analysed surface antigen expression, cell 
morphology, differentiation capacity and gene expression. I confirmed that the HPC7 
cells, derived from ES cells transduced with the LIM-homedomain transcription 
factor Lhx2, possess characteristic stem cell-like features. Hence HPC7 exhibit self-
renewal potential, a c-Kit+ Sca-1+ Lin- phenotype with low Flt3 expression, and 
multilineage differentiation potential in response to appropriate stimuli, although they 
showed very little or no reconstitution capacity when transplanted into irradiated 
recipients (Pinto do, et al., 1998). On the other hand, the FMH9 cells, generated 
from purified bone marrow progenitors co-transduced with HoxA9 and Meis1, 
revealed a more mature phenotype, being positive for Mac1 and Gr1, and 
apparently blocked at the stage of myelomonocytic differentiation. In addition, I 
showed that FMH9 cells have high expression of the stem cell marker Flt3, which 
normally would not be expressed at this stage of lineage differentiation (Adolfsson et 
al., 2001). In section 3.3, I show that FMH9 cells possess the principal 
characteristics of AML cells, that is, high proliferative potential and blocked 
differentiation. Most importantly, as shown by Wang and colleagues (Wang et al., 
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2005), FMH9 cells possess the ability to establish a leukaemia when transplanted 
into irradiated mice. These use of these cell lines also represents a limitation of the 
work, first because they have a different origin; the HPC7 being derived from ES 
cells and the FMH9 cells from adult bone marrow, and also because they are 
transformed cells.  
In conclusion, despite of the limitation mentioned above, HPC7 and FMH9 cells 
represent good models for the comparative study of HSC and AML, in regard to 
understanding the transcriptional and epigenetic regulation of the flt3 gene. 
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CHAPTER 4: 
TRANSCRIPTIONAL REGULATION OF THE 
FLT3 GENE IN HAEMATOPOIETIC AND 
LEUKAEMIC STEM CELLS 
 
4.1 Introduction 
In the past few years accumulating evidence has pointed to a pivotal role for Flt3 as 
a regulator of haematopoietic stem cells, several publications indicating an 
involvement of Flt3 in proliferation, differentiation and survival during the early 
stages of HSCs commitment, although the precise actions of the Flt3 receptor and 
its ligand are still unclear and subject of debate.  
Despite the fact that there is substantial knowledge relating to the pattern of 
activation and nature of mutations in Flt3 in relation to leukaemia (described in 
Section 1.11.5), very little is known about the mechanism of transcriptional 
regulation that controls flt3 gene expression either in leukaemic cells or in normal 
HSCs.  A first hint as to how the normal or mutated flt3 gene might be regulated was 
provided by Holmes and coworkers who demonstrated that the transcription factor 
Pax5 can have a negative effect on its expression (Nutt et al, 1999; Holmes el al, 
2006).  In this latter study, Pax5-/- pro-B-cells were transduced with a retroviral 
vector expressing Pax5 fused to the ligand-binding domain of the human oestrogen 
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receptor (Pax5ER); the activation of this vector upon the addition of β-oestradiol 
resulted in a significant decline in Flt3 expressed at the cell surface and a down 
regulation in flt3 mRNA levels within four hours. Additionally, chromatin 
immunoprecipitation using an antibody against Pax5 revealed direct binding of the 
factor on the flt3 promoter in a region within 200 bp upstream of the transcriptional 
start site.  As described in Section 3.3, Wang and colleagues showed that the 
retroviral expression in myeloid progenitors of Meis1 in combination with HoxA9 
results in a myeloid leukaemia resembling AML within eight weeks, and that this was 
associated with the up regulation of the Flt3 receptor (Wang et al.; 2006).  
Furthermore, the enforced expression of Meis1 in HoxA9-immortalized SCF-
dependent progenitor cells resulted in increased flt3 expression and allowed 
proliferation in the presence of only Flt3 ligand (FL).  ChIP performed on the 
transformed myeloid cells using antibodies against Meis1 (Meis1-FLAG) and HoxA9 
(HoxA9-HA) revealed the recruitment of these two homeodomain transcription 
factors on the proximal promoter and enhancer regions, recruitment of Meis1 on the 
promoter region being accompanied by both H3K4 methylation and acetylation of 
histone 3, suggesting that Meis1 over expression may result in epigenetic 
modifications of histone 3 prior or associated with the activation of flt3 transcription. 
From what I have described above and what is known about the normal and 
leukaemia-associated expression of flt3, it is apparent that there is a need to further 
elucidate the mechanisms of transcriptional and epigenetic regulation of the flt3 
gene.  In this chapter I will describe studies in which I have investigated the gene 
regulatory regions of the flt3 gene in HSCs (represented by the model cell line 
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HPC7) in comparison to myeloid leukaemic cells (represented by the HoxA9/Meis1-
transformed cell line FMH9) and primary sorted HSCs and committed progenitor 
cells.  
The first step in the investigation of the mechanisms of regulation of a particular 
gene commonly involves the location of putative cis-regulatory elements, which can 
be achieved by DNAseI nuclease hypersensitivity mapping (Wu, et al; 1979).  This 
can be followed using chromatin immunoprecipitation to demonstrate the in vivo 
binding of transcription factors and chromatin modifying enzymes and to define the 
modification status of individual histone tail residues.  Finally, functional studies may 
be performed in order to elucidate the importance of the identified cis-regulatory 
regions and the various proteins that have been shown to bind to them. 
4.2 Sequence conservation 
One of the aims of this investigation is to locate and characterize the cis-regulatory 
elements that are involved in the control of flt3 gene expression. Since these 
elements are likely to have been conserved among species, indentifying the peaks 
of sequence homology over the locus is the first step towards locating cis-regulatory 
elements.  The murine flt3 gene is located on chromosome 5 and consists of 24 
exons spread over more than 80 kbp.  A schematic representation of the promoter 
and the first intron is shown in Figure 4.1A.  The flt3 gene is characterized by an 
abundance of repeated sequences and an overall low degree of cross-species 
sequence conservation, as shown by the analysis performed using Genome 
Browser.  The flt3 locus on chromosome 5 is syntenic with multiple species, 
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including human, rat, dog and xenopus, as indicated by the presence of orthologous 
genes (Pan3, Cdx2, Pdx1) in the same orientation upstream and downstream of the 
flt3 gene (data not shown). Figure 4.1 shows the alignment of the human, mouse, 
rat and dog sequences, revealing two regions of particular sequence conservation, 
one centred on the promoter and exon 1 and another in the first intron at 
approximately 7.6 kbp downstream of the transcription initiation site, with a smaller 
region of conservation located approximately 1.3 kbp upstream of the translation 
initiation codon (Figure 4.1B).   
 
Figure 4.1 The flt3 gene promoter region.  (A) Exons 1 and 2 are represented by 
filled boxes with the transcription initiation site indicated by the arrow.  (B) Graphical 
representation of a multispecies alignment taken form the NCBI database showing 
the homology between mouse, human, rat and dog sequences. Blue arrows indicate 
regions of sequence conservation. The transcriptional start site (TSS) is also 
indicated. 
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Analysis of sequence homology performed outside of mammalian species revealed 
(eg in vertebrates) confirmed the intronic region as the unique conserved region 
apart from the exons (not shown). Figure 4.1 also shows that there is a unique 
transcribed RNA, indicated by the grey line in the middle panel. 
4.3 Identification of cis-regulatory elements by DNAseI 
HSS analysis  
In order to further investigate the regions of sequence conservation I performed a 
DNAseI hypersensitive site mapping.  Mapping the DNAseI HSS within nuclear 
chromatin is a well-established and powerful approach for identification of the 
regulatory elements controlling the transcription of a gene.  Two approaches can be 
taken to map HSS: (i) Southern blot hybidization, which allows scanning of a large 
region of the gene body, but is suitable mainly for cell line analysis because of the 
large amount of DNA required; and (ii) Real time PCR, which can be applied to 
small number of cells, therefore making it suitable for the study of primary cells 
(described in Material and Methods). 
4.3.1 Southern blot hybridization approach 
In order to assess the importance of the two conserved regions in the regulation of 
the flt3 gene in HPC7 cells nuclei were treated with increasing concentrations of 
DNAseI and genomic DNA was then extracted as described in Materials and 
Methods.  The DNA (5 µg) was digested with either StuI or BamHI and subsequently 
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blotted and hybridized respectively to probe A or probe B, fragments covering the 
promoter and first intron of the flt3 gene (Figure 4.2A). 
4.3.1.1 HPC7 
Hybridisation of probe A to the blot of StuI-digested DNAs revealed a parental band 
of 8.1 kbp.  This band was present in all the DNA samples, but at higher 
concentrations of DNAseI (60 units) it was partially cleaved into two discrete bands 
of 6.9 kbp and 4.1kbp, corresponding to two HSSs located at -2.4 kbp (HS2) and -
0.15 kbp (HS4), and two minor bands of 2.5 kbp and 4.9 kbp, corresponding to HS1 
and HS3 located at -1.4 kbp and -4kbp relative to the transcription start site (Figure 
4.2).  Hybridisation of probe B to the blot of BamHI-digested DNAs revealed a 
parental band of 18.9 kbp.  In samples derived from nuclei treated with DNaseI the 
parental band was partially cleaved releasing a 8.9 kbp fragment corresponding to 
another HSS (HS5) located at +7.5 kbp (Figure 4.2).  Interestingly, three of the five 
sites (indicated by the red arrows in panel A of Figure 4.2) are positioned over the 
regions of sequence conservation around the promoter (HS4) and in the first intron 
(HS5).  
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Figure 4.2 DNAseI hypersensitive site mapping in HPC7 cells.  (A) Schematic 
representation of the flt3 locus and regions of sequence conservation.  (B) Position 
and length of the fragments generated by StuI and BamHI restriction digestion and 
the location of the probes used for Southern blot.  (C) Identification of hypersensitive 
sites was achieved using StuI/probe A for the promoter region and BamHI/probe B 
for the intronic region.  Probes were radiolabelled with [32p] dCTP and the hybridized 
blot exposed to film overnight.  The position of the HSSs is indicated by the arrows. 
This figure represents the typical result obtained in four independent experiments. 
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4.3.1.2 FMH9 
In order to gain information about possible differences in the regulation of the flt3 
gene in HSCs compared to Flt3+ leukaemic cells, a similar hybridization analysis 
was performed on DNA prepared from DNAseI-treated FMH9 cell nuclei.  As 
expected, hybridization of probe A to the blot of StuI-digested FMH9 DNAs revealed 
the same parental band of 8.1 kbp seen for HPC7.  This band was cleaved at higher 
concentrations (40 units of DNAseI) giving rise to the same bands of 6.9 kbp, 4.9 
kbp and 4.2 kbp (corresponding to HS2, HS3 and HS4) already seen using HPC7, 
and a lower band of 2.5 kbp corresponding to a HSS, indicated as HS4, located at -
4 kbp upstream of the transcription start site (Figure 4.3C).  Hybridization of probe B 
to the blot of BamHI-digested DNAs highlighted the expected parental band of 18.9 
kbp.  The parental band decreased in intensity in proportion to the increased amount 
of DNAseI units used; this band disappeared completely at high concentrations (40 
units) highlighting the presence of a broad region of sensitivity, different from the 
HS5 seen in HPC7 (Figure 4.3C).  
The Southern blot approach revealed the presence in HPC7 cell DNA of three HSS 
in the promoter region, two of which showed a similar degree of hypersensitivity, 
and one in the intronic region (Figure 4.2C).  Corresponding HSS were found to be 
present in FMH9 but showed a different pattern of hypersensitivity, with HS4 
appearing stronger compared to the HS2.  HS5 in FMH9 cell DNA seemed to be 
replaced by a broader region of sensitivity, appearing as a smear rather than a 
discrete band.  
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Figure 4.3 DNAseI Hypersensitive site mapping in FMH9 cells.  (A) Schematic 
representation of the flt3 locus and regions of sequence conservation.  (B) Position 
and length of the fragments generated by StuI and BamHI restriction digestion and 
the location of the probes used for Southern blot.  (C) Identification of hypersensitive 
sites was achieved using StuI/probe A for the promoter region and BamHI/probe B 
for the intronic region.  Probes were radiolabelled with [32p] dCTP and the hybridized 
blot exposed to film overnight.  The position of the HSSs is indicated by the arrows. 
This figure represents the typical result obtained in three independent experiments. 
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4.3.2 Real time PCR approach 
To confirm the findings obtained by Southern blot hybridization and to define more 
precisely the region of hypersensitivity across the promoter and first intron of the flt3 
locus, the relative amount of intact DNA was determined by quantitative real time 
PCR, comparing DNAseI-digested versus undigested DNA samples from HPC7 and 
FMH9 nuclei.  For this purpose specific primers spanning the regions of interest of 
the flt3 locus were designed (details provided in Materials and Methods).  The 
analysis of the HS1 was not possible because the abundance of repeats in the 
vicinity of this HSS precluded the design of suitable PCR primers.  The data 
represented in Figure 4.4 depicts the ratio between DNAseI-digested versus 
undigested DNA, reflecting the relative amount of digestion (represented on the Y-
axis) compared to the position relative to the translation start site (represented on 
the X-axis). 
4.3.2.1 HPC7 
PCR analysis of DNA prepared from DNAseI (60 units)-treated versus untreated 
HPC7 DNA revealed the presence of three HSS positioned at -2.4 kbp (HS2), -1.35 
kbp (HS3) and -150 kbp (HS4) in the promoter region, perfectly correlating with the 
sites determined by Southern blot hybridization.  The analysis of the intronic HSS 
also confirmed the presence of HS5 positioned at +7.5 kbp.  Interestingly the PCR 
amplification across this region also revealed the existence of a second peak of 
DNAseI hypersensitivity located at +7.75 kbp, although this exhibited a lower degree 
of sensitivity (Figure 4.4, top panel).   
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4.3.2.2 FMH9 
The analysis of the promoter and intronic regions in DNA obtained from FMH9 also 
confirmed the presence of the four HSS observed in HPC7.  The distance from the 
transcription start site and the correlation of the HSS with the peaks of sequence 
homology are indicated in Figure 4.4 (top panel).  Interestingly, the two cell lines 
show a similar pattern and degree of sensitivity in the promoter region, but the HS5 
site in the HPC7 cells is characterized by a high degree of sensitivity compared to 
the other sites found in the same cell line; this observation does not reflect what is 
seen in the FMH9 cell line, since the different peaks show a similar degree of 
sensitivity (Figure 4.4, lower panel).  This analysis shows that comparing the HSC 
and leukaemia cell lines there are both similarities and differences in the flt3 
promoter and first intron chromatin structures, suggesting common and distinct 
regulatory features. 
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Figure 4.4. Analysis of DNAseI hypersensitivity at the flt3 locus.  Nuclei from 
both HPC7 and FMH9 cell lines were treated with 0 or 60 units of DNAseI and the 
purified DNA was used as the template for quantitative real time PCR reactions.  
The ratio between digested and undigested samples reflects the extent of 
hypersensitivity across regions covered by the PCR amplicons. The top panel 
shows a schematic representation of HSS mapped onto the flt3 locus relative to the 
translational start site, the position of the oligos used, as well as the inter-species 
sequence conservation and the presence of repeated sequences. All graphics are 
aligned to the flt3 locus schematic. This figure represents the typical result obtained 
in five independent experiments in which each PCR was performed in triplicate. The 
width of the bars in the plot reflects the length of the amplicons. PCR amplicons 
overlap as indicated. 
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4.3.2.3 Primary KSL 
As a result of the small numbers of primary KSL cells, the amount of DNA 
obtainable following DNAseI digestion was only sufficient to allow an analysis 
restricted to the regions of the HSSs.  In the case of Flt3+ KSL cells, which 
represent the MPPs, both HS3 and HS5 domains showed a high degree of 
hypersensitivity to 60 units of DNAseI when compared to the undigested DNA 
control.  Analysis of the HS2 region revealed very little digestion, while no 
hypersensitivity was detected at the HS4 element (Figure 4.5, top panel).  A similar 
analysis of Flt3- KSL cells, which represent LT- and ST-HSCS, treated with the 
same amount of DNAseI revealed a very pronounced sensitivity to nuclease 
digestion at the promoter region at HS3, equivalent to that observed in Flt3+ cells.  
In contrast, no hypersensitivity was observed at HS5 in the intronic region or at HS2 
and HS4 in the promoter (Figure 4.5, lower panel).  These findings suggest that the 
intronic HS5 region may be associated with the activation of flt3 expression during 
the transition from ST-HSCs to MPPs. 
4.3.2.4 Primary CMP 
Having demonstrated that HS3 appears relevant in both Flt3- and Flt3+ KSL HSCs 
and that the intronic HS5 could be linked to the activation of flt3 gene expression in 
MPPs, the next step was to perform DNAseI HSS analysis in a down stream cell 
population that has lost the expression of flt3 following commitment.  For this reason 
CMP, GMP and MEP committed progenitors were sorted (as described in section 
3.5) and subjected to the same analysis described for KSL cells.  The small number 
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of cells obtained also limited this approach.  DNA isolated from CMP cells digested 
with 60 units of DNAseI exhibited no sensitivity at any of the cis-regulatory regions 
(Figure 4.6A).  Unsurprisingly, since the expression of the flt3 gene has been down 
regulated during the transition from MPP to more committed progenitors, neither 
GMP or MEP cell DNAs showed any signs of hypersensitivity at the selected regions 
(Figure 4.6B and C). No specific positive control have been used for this experiment, 
however the DNAseI HSS mapping in these cells was performed in parallel with the 
KSL cells (see section 4.3.2.3), ensuring the efficiency of this approach. 
 
Figure 4.5 DNAseI Q-PCR HSS analysis of the flt3 promoter and intronic 
region in primary Flt3+ and Flt3- KSL cells.  Nuclei from sorted KSL cells were 
treated with 0 or 60 units of DNAseI and purified DNA was used for Q-PCR 
amplification using primers spanning the cis-regulatory regions of interest.  The 
amount of DNAseI digestion at HS2-5 and two internal control regions are plotted on 
the Y-axis and are aligned to the schematic of the flt3 locus (top panel).  Details of 
the PCR primers used are provided in Materials and Methods. This figure represents 
the typical result obtained in five independent experiments in which each PCR was 
performed in triplicate. 
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Figure 4.6 Analysis of DNAseI hypersensitivity at the flt3 locus in sorted CMP, 
GMP and MEP populations.  Sorted CMP, GMP and MEP cells were digested with 
60 units of DNAseI and purified DNA from each cell population was used to 
measure hypersensitivity at the flt3 locus relative to undigested cells.  Ratios of Q-
PCR amplification between digested and undigested cells shown on the Y-axis 
reflect the amount of digestion.  Regions of interest and their relative sequence 
conservation are indicated in the top panel. This figure represents the typical result 
obtained in three independent experiments in which each PCR was performed in 
triplicate. 
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4.4 Epigenetic regulation of the flt3 locus in normal versus 
leukaemia-like cells 
 
In order to characterize the epigenetic profile on the flt3 locus in HSC-like cells and 
in the Flt3+ leukaemia model cell line, I next assessed the distribution of histone 
marks that are associated with transcriptional activity or silencing (Turner; 2005), or 
that have been reported to be specifically enriched in leukaemic cells (eg 
H3K79me3) (Krivtsov et al.; 2008). I also wish to correlate the histone marks with 
the presence of the hypersensitive sites (determined in section 4.3) across the flt3 
locus. Formaldehyde cross-linkied chromatin immunoprecipitation (X-ChIP) analysis 
was performed using specific antibodies against acetyl groups on lysine 9 and 8 of 
histones 3 and 4, respectively (H3K9ac and H4K8ac), and the dimethylation of 
lysine 9 and the trimethylation of lysine 4 and 79 on histone 3 (H3K9me2, H3K4me3 
and H3K79me3).  Immunoprecipitated DNA was analysed by real time PCR, 
focussing on the regions surrounding the cis-regulatory elements identified by 
DNAseI HSS assay in order to determine the pattern of histone modifications around 
these elements. The relative enrichment displayed in each plot of this section 
corresponds to the ratio Bound specific IgG/Bound non-specific IgG (purified normal 
IgG) obtained by subtracting the non-specific binding from the IgG/protein A-G 
agarose bound. Specific patterns of modifications were determined after 
normalisation to the basal level across the locus, which provides the internal control. 
No reference to external negative or positive controls is shown. 
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4.4.1 H3K4me3 
The analysis of anti-H3K4me3 immunoprecipitated DNA from HPC7 cells, a mark 
generally associated with transcriptionally active chromatin, revealed the presence 
of this modification just upstream of the transcriptional start site, and most 
predominantly in the region encompassing the intronic HS5 element.  A similar 
analysis performed on FMH9 cells highlighted the broader presence of this mark on 
the intronic domain compared to that seen in HPC7 and a distinct similar profile 
around the promoter consisting of modification in the region of HS3 and a shift of the 
major peak away from HS4 to a position downstream of exon 1 (Figure 4.7). 
4.4.2 H4K8ac 
The H4K8Ac modification, a histone mark normally associated with active 
chromatin, seemed to exhibit no significant enrichment over the flt3 locus in HPC7 
cells, whereas in FMH9 cells the mark appears to be quite predominant, and in 
particular at the upstream HSS, HS1 and HS2, downstream of exon 1 and at the 
intronic HS5 element (Figure 4.8). 
4.4.3 H3K9ac  
Acetylation at histone 3 lysine 9, a histone modification tipically associated with 
active chromatin, was very marked upstream of the promoter and at the intronic HS5 
region in HPC7.  In contrast, in FMH9 the peak of modification around the promoter 
was down stream of exon 1, although a similar degree of modification was apparent 
at HS5, with a large peak of acetylation immediately upstream this regulatory 
domain (Figure 4.9).  
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4.4.4 H3K9me2 
The analysis of DNA prepared from chromatin immunoprecipitated with an antibody 
anti-H3K9me2, an histone mark associated with gene repression, exhibited no 
significant peaks of modification across the flt3 promoter/intron 1 region in HPC7 
cells.  However, a similar analysis of chromatin from FMH9 cells revealed an 
abundance of this mark in the region encompassing HS2 (Figure 4.10).  
4.4.5 H3K79me3  
No evidence was obtained for a significant concentration of this mark around the 
promoter and intron 1 regions of the flt3 locus in either HPC7 or FMH9 cells, 
although a small degree of enrichment was perhaps seen in HPC7 at the 
transcription initiation site (Figure 4.11). 
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Figure 4.7 Analysis of the H3K4me3 histone modification at the flt3 locus.  X-
ChIP experiments were performed on chromatin derived from both HPC7 and FMH9 
cell lines using an antibody against the tri-methylation modification on lysine 4 of 
histone 3.  Purified immunoprecipitated DNA was used as a template for Q-PCR 
amplifications to determine the relative enrichment compared to the control IgG 
ChIP material.  The plots represent the relative enrichment on the Y-axis and the 
position relative to the transcriptional start site on the X-axis.  The figure shows the 
alignment of the histograms with a schematic representation of the flt3 promoter and 
first intron.  DNAseI HSSs are indicated by red arrows. Dashed line represent the 
basal level across the locus. This figure represents the typical result obtained in 
three independent experiments in which each PCR was performed in triplicate. The 
width of the bars in the plot reflects the length of the amplicons. PCR amplicons 
overlap as indicated. 
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Figure 4.8 Analysis of the H4K8Ac histone modification at the flt3 locus. X-
ChIP experiments were performed on chromatin derived from both HPC7 and FMH9 
cell lines using an antibody against the acetylation of lysine 8 on histone 4.  Purified 
immunoprecipitated DNA was used as a template for Q-PCR amplifications to 
determine the relative enrichment compared to the control IgG ChIP material.  The 
plots represent the relative enrichment on the Y-axis and the position relative to the 
transcriptional start site on the X-axis.  The figure shows the alignment of the 
histograms with a schematic representation of the flt3 promoter and first intron.  
DNAseI HSSs are indicated by red arrows. Dashed line represent the basal level 
across the locus. This figure represents the typical result obtained in four 
independent experiments in which each PCR was performed in triplicate. The width 
of the bars in the plot reflects the length of the amplicons. PCR amplicons overlap 
as indicated. 
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Figure 4.9 Analysis of the H3K9Ac histone modification at the flt3 locus. X-
ChIP experiments were performed on chromatin derived from both HPC7 and FMH9 
cell lines using an antibody against the acetylation of lysine 9 on histone 3.  Purified 
immunoprecipitated DNA was used as a template for Q-PCR amplifications to 
determine the relative enrichment compared to the control IgG ChIP material.  The 
plots represent the relative enrichment on the Y-axis and the position relative to the 
transcriptional start site on the X-axis.  The figure shows the alignment of the 
histograms with a schematic representation of the flt3 promoter and first intron.  
DNAseI HSSs are indicated by red arrows. Dashed line represent the basal level 
across the locus. This figure represents the typical result obtained in four 
independent experiments in which each PCR was performed in triplicate. The width 
of the bars in the plot reflects the length of the amplicons. PCR amplicons overlap 
as indicated. 
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Figure 4.10 Analysis of the H3K9Me2 histone modification at the flt3 locus. X-
ChIP experiments were performed on chromatin derived from both HPC7 and FMH9 
cell lines using an antibody against the dimethylation of lysine 9 on histone 3.  
Purified immunoprecipitated DNA was used as a template for Q-PCR amplifications 
to determine the relative enrichment compared to the control IgG ChIP material.  
The plots represent the relative enrichment on the Y-axis and the position relative to 
the transcriptional start site on the X-axis.  The figure shows the alignment of the 
histograms with a schematic representation of the flt3 promoter and first intron.  
DNAseI HSSs are indicated by red arrows. Dashed line represent the basal level 
across the locus. This figure represents the typical result obtained in three 
independent experiments in which each PCR was performed in triplicate. The width 
of the bars in the plot reflects the length of the amplicons. PCR amplicons overlap 
as indicated. 
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Figure 4.11 Analysis of the H3K79me3 histone modification at the flt3 locus. X-
ChIP experiments were performed on chromatin derived from both HPC7 and FMH9 
cell lines using an antibody against the tri-methylation of lysine 79 of histone 3.  
Purified immunoprecipitated DNA was used as a template for Q-PCR amplifications 
to determine the relative enrichment compared to the control IgG ChIP material.  
The plots represent the relative enrichment on the Y-axis and the position relative to 
the transcriptional start site on the X-axis.  The figure shows the alignment of the 
histograms with a schematic representation of the flt3 promoter and first intron.  
DNAseI HSSs are indicated by red arrows. Dashed line represent the basal level 
across the locus. This figure represents the typical result obtained in two 
independent experiments in which each PCR was performed in triplicate. The width 
of the bars in the plot reflects the length of the amplicons. PCR amplicons overlap 
as indicated. 
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4.5 Transcriptional regulation of the flt3 locus in normal 
versus leukaemia-like cells 
4.5.1 Bioinformatic analysis of potential cis-regulatory regions 
Different histone modifying enzymes, such as acetylases and deacetylases, can be 
recruited to a gene locus by specific transcription factors and at the same time their 
activity can be a pre-requisite to allow transcription factor binding to the DNA.  In 
order to identify possible trans-regulators of flt3 expression in HSCs and leukaemia 
cells, I performed an alignment of the genomic DNA sequences from human, 
mouse, rat and dog covering those regions of the flt3 promoter and first intron that 
had been shown to exhibit HSS and specific epigenetic modifications in HPC7 and 
FMH9 cells.  The search for potential transcription factor binding sites was 
performed using MAT-Inspector and Transcription Element Search System 
(T.E.S.S) software. 
In those regions (HS3, 4 and 5) for which the sequence information allowed 
alignment of all four of the mammalian genomes, and showed strong conservation 
(shown in black shading), a number of good matches to known transcription factor 
consensus binding sites were identified.  Only mouse and rat sequences could be 
aligned across HS2 (shown in grey shading).  Conserved concensus binding sites 
for c-Myb (blue), Ets (green), RUNX1 (red), PU.1 (orange), GATA (pale blue), 
C/EBPα (beige), Pax5 (purple), Pbx/Meis1 (maroon) and Sox2 (pink) were identified 
in one or more of the HSS as indicated.in Figures 4.12-15. All the consensus 
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binding sites shown in these figures were selected on the basis of an arbitrary 
threshold of 90% of homology against the consensus matrix.     
     
Figure 4.12. Putative transcription factor binding sites in the flt3 HS2 
regulatory element.  Multi-species alignment of mammalian genome sequences 
highlighting the sequence conservation (in grey) in the region of HS2.  The blue, 
green and red boxes highlight the potential c-Myb, Ets and AML1 binding sites, 
respectively. 
 
Figure 4.13 Putative transcription factor binding sites in the flt3 HS3 
regulatory element.  Multi-species alignment of mammalian genome sequences 
highlighting the sequence conservation (in black and grey) in the region of HS3.  
The blue, green, red, beige and pale blue boxes highlight the potential c-Myb, Ets, 
AML1, c/EBP and GATA bin 
 111 
 
Figure 4.14 Putative transcription factor binding sites in the flt3 HS4 
regulatory element.  Multi-species alignment of mammalian genome sequences 
highlighting the sequence conservation (in black and grey) in the region of HS4.  
The green, red, orange and purple boxes highlight the potential Ets, AML1, PU.1 
and Pax5 binding sites, respectively. 
 
Figure 4.15 Putative transcription factor binding sites in the flt3 intronic HS5 
regulatory element.  Multi-species alignment of mammalian genome sequences 
highlighting the sequence conservation (in black and grey) in the region of HS5.  
The blue, orange, beige, pale blue and maroon boxes highlight the potential c-Myb, 
PU.1, C/EBPα, GATA and Pbx/Meis1 binding sites, respectively.  
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4.5.2 In vivo transcription factor binding to the flt3 promoter and 
intron 1 regulatory elements 
As described in Section 4.6.1, the regions of nuclease hypersensitivity encompass 
several binding sites for Ets, GATA, c-Myb, C/EBPα and other stem cell- and 
leukaemia-associated transcription factors.  Therefore, I next investigated by X-ChIP 
which of the proteins known to be expressed are actually bound in vivo to the flt3 
promoter and/or intron 1 in HPC7 and FMH9 cells.  ChIP products were analysed by 
real time PCR and relative enrichments were determined by comparison with the 
matching IgG control.  
4.5.2.1 HoxA9, Meis1, Pbx1/2  
As mentioned above, Wang and colleagues reported the direct binding of HoxA9 
and Meis1 to the flt3 promoter in myeloid leukaemia cells (Wang et al.; 2006). As 
described in section 3.3 the cell model used was generated by retroviral co-
transduction of bone marrow cells with HoxA9-HA and Meis1-FLAG. In order to 
assess the direct interaction of these two transcription factors, Wang and colleagues 
performed ChIP analysis using antibodies against the FLAG and HA tags on the 
transforming exogenous Meis1 and HoxA9 (Wang et al.; 2006).  In order to confirm 
these findings I adopted the same approach in FMH9 cells.  In agreement with 
previous observations, ChIP assays using α-FLAG and α-HA antibodies revealed 
the binding of both HoxA9 (Figure 4.16, lower panel) and Meis1 (Figure 4.17, lower 
panel) on the HS3 region.  No enrichments were observed at HS2 or HS5.  HS4 was 
not investigated due to the lack of sufficient purified DNA.  ChIP analysis was also 
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performed with chromatin from both HPC7 and FMH9 cells, using antibodies against 
the N-terminus of HoxA9 and the C-terminus of Meis1.  These latter studies 
indicated the recruitment of both HoxA9 and Meis1 at HS3, but not at other regions, 
in both HSC- and leukaemia-like cells (Figures 4.16 and 4.17, upper and middle 
panels). 
Wang and coworkers also provided evidence for recruitment of Meis1/Pbx 
complexes on leukaemia-associated gene promoters.  Therefore, I next investigated 
the in vivo binding of both Pbx1 and Pbx2 to the flt3 locus.  PCR analysis of Pbx1 
ChIP DNA demonstrated binding at the HS3 region only, with a similar profile in 
HPC7 cells to that observed for HoxA9 and Meis1 (Figure 4.18). In contrast, the 
analysis of occupancy of the flt3 promoter by Pbx1 only revealed a small enrichment 
at the HS3 region in FMH9 cells. No significant binding of Pbx2 could be shown, 
using chromatin from either in HPC7 or in FMH9 cells (Figure 4.19). No positive 
controls are shown for Pbx2 in this section, however the antibody used has been 
proved to ChIP efficiently (Dasse et al, unpublished data). 
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Figure 4.16 X-ChIP analysis of in vivo binding of HoxA9 on the flt3 locus.  X-
ChIP analysis was performed on chromatin derived from HPC7 and FMH9 cells 
using antibodies directed against the N-terminus of HoxA9 in both cell lines 
(represented in the top and middle histograms) or the HA-tag of HA-HoxA9 in FMH9 
cells (lower panel).  Specific ChIP DNA fragments encompassing the four HSS 
(indicated by the red arrows in the top schematic) and two internal control regions 
were quantified by Q-PCR to determine their enrichment relative to the control IgG 
ChIP.  The figure shows histograms depicting the extent of enrichment aligned with 
the structure of the flt3 promoter and first intron.  ND: not determined, due to the 
lack of sufficient ChIP DNA material. This figure represents the typical result 
obtained in three independent experiments in which each PCR was performed in 
triplicate from one ChIP experiment. Error bars represent the standard error of the 
mean. 
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Figure 4.17 X-ChIP analysis of in vivo binding of Meis1 on the flt3 locus.  X-
ChIP analysis was performed on chromatin derived from HPC7 and FMH9 cells 
using antibodies directed against the C-terminus of Meis1 in both cell lines 
(represented in the top and middle histograms) or the FLAG-tag of FLAG-Meis1 in 
FMH9 cells (lower panel).  Specific ChIP DNA fragments encompassing the four 
HSS (indicated by the red arrows in the top schematic) and two internal control 
regions were quantified by Q-PCR to determine their enrichment relative to the 
control IgG ChIP.  The figure shows histograms depicting the extent of enrichment 
aligned with the structure of the flt3 promoter and first intron.  ND: not determined, 
due to the lack of sufficient ChIP DNA material. This figure represents the typical 
result obtained in three independent experiments in which each PCR was performed 
in triplicate from one ChIP experiment. Error bars represent the standard error of the 
mean. 
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Figure 4.18 X-ChIP analysis of in vivo binding of Pbx1 on the flt3 locus. X-ChIP 
analysis was performed on chromatin derived from HPC7 and FMH9 cells using 
using an antibody directed against the N-terminus of Pbx1.  Specific ChIP DNA 
fragments encompassing the four HSS (indicated by the red arrows in the top 
schematic) and two internal control regions were quantified by Q-PCR to determine 
their enrichment relative to the control IgG ChIP.  The figure shows histograms 
depicting the extent of enrichment aligned with the structure of the flt3 promoter and 
first intron. This figure represents the typical result obtained in three independent 
experiments in which each PCR was performed in triplicate from one ChIP 
experiment. Error bars represent the standard error of the mean.
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Figure 4.19 ChIP analysis of in vivo binding of Pbx2 on the flt3 locus. X-ChIP 
analysis was performed on chromatin derived from HPC7 and FMH9 cells using 
using an antibody directed against the N-terminus of Pbx2.  Specific ChIP DNA 
fragments encompassing the four HSS (indicated by the red arrows in the top 
schematic) and two internal control regions were quantified by Q-PCR to determine 
their enrichment relative to the control IgG ChIP.  The figure shows histograms 
depicting the extent of enrichment aligned with the structure of the flt3 promoter and 
first intron. This figure represents the typical result obtained in two independent 
experiments in which each PCR was performed in triplicate from one ChIP 
experiment. Error bars represent the standard error of the mean. 
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4.5.2.2 c-Myb  
ChIP using an anti-c-Myb antibody on chromatin derived from both HPC7 and FMH9 
cells resulted in a clear enrichment of sequences encompassing HS3.  A lesser 
degree of enrichment was also observed over the intronic HS5 region, this being 
somewhat more pronounced in HPC7 cells compared to FMH9 (Figure 4.20). 
4.5.2.3 Ets and GATAs  
Since several putative Ets and GATA binding sites were identified in four of the flt3 
HSS, I examined the in vivo binding of PU.1, GATA-1 and GATA-2.  The analysis of 
the GATA factors was restricted to HPC7s since their expression was not detected 
in FMH9 cells (see Figure 3.5, Section 3.3.3).  GATA1 ChIP revealed in vivo binding 
of this factor on HS2, HS5 and most significantly on the HS3 region (Figure 4.21, 
upper panel).  No binding of GATA1 was detected on the HS4 element.  Similar 
analysis of GATA2 in vivo binding showed this to occur exclusively at HS3 (Figure 
4.21, lower panel).  Direct interaction of PU.1 with the flt3 locus was detected on the 
HS3 element in HPC7, while no interaction with the promoter or intron was seen in 
FMH9 cells (Figure 4.22).   
4.5.2.4 Sox2 
Analysis of the in vivo binding of Sox2, another stem cell-associated transcription 
factor for which concensus binding sites were identified in the flt3 HSS, was only 
performed using HPC7 chromatin as expression could be detected in these cells but 
not in FMH9.  Interestingly, this revealed the interaction of Sox2 with the intronic 
HS5 region, but not significantly with the promoter HSS (Figure 4.23). 
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4.5.2.5 C/EBPα  
Since recent publications have highlighted a direct link in some leukaemias between 
Flt3 activating mutations and altered C/EBPα expression, I investigated whether the 
concensus binding sites found in the flt3 gene are reflected by in vivo binding of his 
leucine zipper transcription factor in either of the cell models. C/EBPα ChIP of HPC7 
cells revealed the binding of the protein on both the promoter (HS3) and the intronic 
HS5 regions (Figure 4.24, upper panel), whereas in FMH9 binding was restricted to 
the intronic element (Figure 4.24, lower panel). 
4.5.2.6 Runx1 
Good matches to the concensus binding site for Runx1 were identified in three of 
the four HSS, and of these two, HS3 and HS5 were shown to be enriched in 
chromatin precipitated by Runx1 ChIP from HPC7 cells (Figure 4.25, upper panel). 
The bioinformatic analysis did not reveal the presence of Runx binding sites in the 
HS5 elements, hence suggesting that the in vivo interaction of this transcription 
factor could be mediated by other protein directly interacting with the flt3 intronic 
regulatory element. In the same analysis performed in FMH9 cells none of the sites 
was convincingly shown to bind Runx1 (Figure 4.25, lower panel). 
4.5.2.7 MLL 
Many research groups have reported the importance of the MLL methyltransferase 
in both haematopoiesis and leukaemia and my data has demonstrated differences 
between HPC7 and FMH9 cells with respect to the methylation status of histone H3 
across the flt3 promoter/intron region (see Section 4.5.1).  MLL ChIP revealed in 
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vivo binding of the protein to the flt3 locus in HPC7 at HS2, HS3 and HS5 (Figure 
4.26, upper panel), but little or no evidence for its presence at any position on 
chromatin obtained from FMH9 cells (Figure 4.26, lower panel). 
 
Figure 4.20 In vivo binding of c-Myb at the flt3 locus.  Formaldehyde cross-
linked chromatin from both HPC7 and FMH9 cells was immunoprecipitated using an 
antibody against the C-terminus of c-Myb and the resulting purified DNA was 
analysed by Q-PCR using primers covering the four HSS (indicated in the top panel 
by the red arrows) and two internal controls.  Relative enrichments were determined 
versus the control IgG ChIP.  Each histogram represents the relative enrichment on 
the Y-axis and the position relative to the transcriptional start site on the X-axis, and 
is aligned with the structure of the flt3 gene represented in the top panel. ND: not 
determined due to the lack of sufficient DNA material for Q-PCR amplification. This 
figure represents the typical result obtained in two independent experiments in 
which each PCR was performed in triplicate from one ChIP experiment. Error bars 
represent the standard error of the mean. 
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Figure 4.21 In vivo binding of GATA factors at the flt3 locus. Formaldehyde 
cross-linked chromatin from HPC7 cells was immunoprecipitated using an antibody 
against the C-terminus of either GATA1 (top histogram) or GATA2 (bottom 
histogram) and the resulting purified DNA was analysed by Q-PCR using primers 
covering the four HSS (indicated in the top panel by the red arrows) and two internal 
controls.  Relative enrichments were determined versus the control IgG ChIP.  Each 
histogram represents the relative enrichment on the Y-axis and the position relative 
to the transcriptional start site on the X-axis, and is aligned with the structure of the 
flt3 gene represented in the top panel. This figure represents the typical result 
obtained in two independent experiments in which each PCR was performed in 
triplicate from one ChIP experiment. Error bars represent the standard error of the 
mean. 
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Figure 4.22 In vivo binding of PU.1 at the flt3 locus. Formaldehyde cross-linked 
chromatin from both HPC7 and FMH9 cells was immunoprecipitated using an 
antibody against the C-terminus of PU.1 and the resulting purified DNA was 
analysed by Q-PCR using primers covering the four HSS (indicated in the top panel 
by the red arrows) and two internal controls.  Relative enrichments were determined 
versus the control IgG ChIP.  Each histogram represents the relative enrichment on 
the Y-axis and the position relative to the transcriptional start site on the X-axis, and 
is aligned with the structure of the flt3 gene represented in the top panel. This figure 
represents the typical result obtained in four independent experiments in which each 
PCR was performed in triplicate from one ChIP experiment. Error bars represent the 
standard error of the mean. 
.
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Figure 4.23 In vivo binding of Sox2 at the flt3 locus. Formaldehyde cross-linked 
chromatin from HPC7 cells was immunoprecipitated using an antibody against the 
N-terminus of Sox2 and the resulting purified DNA was analysed by Q-PCR using 
primers covering the four HSS (indicated in the top panel by the red arrows) and two 
internal controls.  Relative enrichments were determined versus the control IgG 
ChIP.  Each histogram represents the relative enrichment on the Y-axis and the 
position relative to the transcriptional start site on the X-axis, and is aligned with the 
structure of the flt3 gene represented in the top panel. This figure represents the 
typical result obtained in two independent experiments in which each PCR was 
performed in triplicate from one ChIP experiment. Error bars represent the standard 
error of the mean. 
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Figure 4.24 In vivo binding of C/EBPα at the flt3 locus. Formaldehyde cross-
linked chromatin from both HPC7 and FMH9 cells was immunoprecipitated using an 
antibody against C/EBPα and the resulting purified DNA was analysed by Q-PCR 
using primers covering the four HSS (indicated in the top panel by the red arrows) 
and two internal controls.  Relative enrichments were determined versus the control 
IgG ChIP.  Each histogram represents the relative enrichment on the Y-axis and the 
position relative to the transcriptional start site on the X-axis, and is aligned with the 
structure of the flt3 gene represented in the top panel. This figure represents the 
typical result obtained in four independent experiments in which each PCR was 
performed in triplicate from one ChIP experiment. Error bars represent the standard 
error of the mean. 
                        .
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Figure 4.25 In vivo binding of Runx1 at the flt3 locus. Formaldehyde cross-linked 
chromatin from both HPC7 and FMH9 cells was immunoprecipitated using an 
antibody against against the C-terminus of Runx1 and the resulting purified DNA 
was analysed by Q-PCR using primers covering the four HSS (indicated in the top 
panel by the red arrows) and two internal controls.  Relative enrichments were 
determined versus the control IgG ChIP.  Each histogram represents the relative 
enrichment on the Y-axis and the position relative to the transcriptional start site on 
the X-axis, and is aligned with the structure of the flt3 gene represented in the top 
panel. This figure represents the typical result obtained in five independent 
experiments in which each PCR was performed in triplicate from one ChIP 
experiment. Error bars represent the standard error of the mean. 
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Figure 4.26 In vivo binding of MLL1 at the flt3 locus. Formaldehyde cross-linked 
chromatin from both HPC7 and FMH9 cells was immunoprecipitated using an 
antibody against against the C-terminus of MLL1 and the resulting purified DNA was 
analysed by Q-PCR using primers covering the four HSS (indicated in the top panel 
by the red arrows) and two internal controls.  Relative enrichments were determined 
versus the control IgG ChIP.  Each histogram represents the relative enrichment on 
the Y-axis and the position relative to the transcriptional start site on the X-axis, and 
is aligned with the structure of the flt3 gene represented in the top panel. This figure 
represents the typical result obtained in two independent experiments in which each 
PCR was performed in triplicate from one ChIP experiment. Error bars represent the 
standard error of the mean. 
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4.5.3 Evaluation of the relative importance of c-Myb and C/EBPα  in 
the transcriptional regulation of flt3. 
In section 4.6.2 I demonstrated the in vivo interaction of several transcription factors 
with the regulatory elements of the flt3 locus.  This analysis, performed in HSC-like 
versus AML-like cell lines, revealed some striking differences regarding the in vivo 
binding of c-Myb (section 4.6.2.2) and C/EBPα (section 4.6.2.5), with binding of the 
latter in particular being restricted to the intronic region only in FMH9 cells.  
Therefore, in order to further elucidate the molecular pathways regulating flt3 
expression, I next performed a gene expression manipulation study in both HSC- 
and AML-like cells, by either silencing or over expressing c-Myb or C/EBPα.  
For the knock down experiments several shRNA vectors have been used to validate 
our results. More over, a non-effective scrambled shRNA vector was used a 
negative control to ensure that the c-Myb and C/EBPα knock down effect were 
specific, therefore avoiding off target effects. 
Furthermore, FMH9 cells cannot be efficiently transfected using standard 
nucleofector reagents (AMAXA), resulting in a cell death higher then 80% after 24 
hours in culture. Because to the high cell death, the only analysis presented in the 
following sections was carried out by Q-PCR, with cells available after sorting not 
being in a sufficient number for protein analysis. 
4.5.3.1 Downregulation studies 
RNA interference mediated silencing of both transcription factors was achieved by 
transfecting both HPC7 and FMH9 cells with plasmids containing short hairpin RNAs 
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(shRNA) sequences or their corresponding empty control plasmids.  Cells were co-
transfected with GFP plasmid in order to enable sorting of transfected cells by flow 
cytometry. The transcript abundance after transfection was evaluated by Q-PCR. 
c-Myb - HPC7 and FMH9 cells were transfected with either c-myb shRNA plasmid 
(shc-Myb) or its respective control plasmid (pSiren) together with the GFP plasmid.  
24 hours later the transfection efficiency was assessed and GFP-positive cells were 
sorted.  Total RNA was then extracted from GFP-positive cells and analysed by Q-
PCR to investigate the expression levels of both c-myb and flt3.  This analysis 
revealed a 40% downregulation of c-myb mRNA in HPC7, which consequently 
resulted in a 60% decrease of flt3 transcript expression (Figure 4.27 panel A). Q-
PCR analysis of c-myb silencing performed in FMH9 cells also highlighted a 
dramatic downregulation of both c-myb (90%) and flt3 (75%) mRNA expression 
(Figure 4.27 panel B), pointing out, in conjunction with the X-ChIP data presented in 
figure 4.20, at the direct involvement of c-myb in the regulation of flt3.    
C/EBPα - Q-PCR analysis of C/EBPα shRNA plasmid (shC/EBPα) transfection in 
HPC7 revealed a 63% decrease in C/EBPα expression compared to cells 
transfected with the negative control plasmid pGFP-V-R. Interestingly, no 
differences were observed in flt3 mRNA expression (Figure 4.28 panel A).  Notably, 
the down regulation of C/EBPα (40%) in FMH9 was followed by a marked reduction 
in flt3 mRNA expression (50%) (Figure 4.28 panel B). This observation is consistent 
with the specific recruitment of C/EBPα to the HS5 intronic element of the flt3 gene 
(Figure 4.24), indicating a key role for C/EBPα in the regulation of flt3 expression in 
leukaemia-like cells. 
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Figure 4.27 Downregulation of c-myb levels by shRNA.  Q-PCR analysis of c-
Myb and flt3 mRNA expression in HPC7 versus FMH9 after transfection with c-Myb 
shRNA or its relative empty control vector. Gapdh was used as the housekeeping 
control gene and each PCR reaction was performed for 40 cycles. These data are 
representative of a single experiment, with each PCR performed in triplicate. The 
two-tailed p value was determined by paired t-test. Statistical significance: **<0.01, 
*<0.05. Error bars represent the standard error of the mean. 
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Figure 4.28 Downregulation of C/EBPα levels by shRNA.  Q-PCR analysis of 
C/EBPα and flt3 mRNA expression in HPC7 versus FMH9 after transfection with 
C/EBPα shRNA (shC/EBPα) or its relative empty control vector. Gapdh was used as 
the housekeeping control gene and each PCR reaction was performed for 40 cycles. 
These data are representative of a single experiment, with each PCR performed in 
triplicate. Results were confirmed in 3 to 4 independent experiments. The two-tailed 
p value was determined by paired t-test. Statistical significance: ***<0.001, *<0.05. 
Error bars represent the standard error of the mean. 
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4.5.3.1 Overexpression studies 
The overexpression of c-myb and C/EBPα was achieved by transfecting HPC7 and 
FMH9 cells with plasmids containing the full cDNA sequences compared to their 
corresponding empty control plasmids.  Cells were co-transfected with GFP plasmid 
in order to enable sorting of transfected cells. 
c-Myb - 24 hours after trasfection with either a c-Myb expression vector 
(pcDNA3Myb) or its relative control plasmid, HPC7 and FMH9 cells were sorted 
based on GFP expression and total RNA from GFP-positive cells was extracted.  Q-
PCR analysis was performed to assess the expression of both c-myb and flt3, and 
revealed the over-expression of c-myb in HPC7 (Figure 4.29 panel A), while the 
mRNA level of flt3 was unaffected.  Interestingly, the overexpression of c-myb in 
FMH9 (3.7 times) resulted in a significant up regulation of flt3 RNA (Figure 4.29 
panel B). 
C/EBPα - Similar to what I had observed for c-Myb, Q-PCR analysis of C/EBPα 
overexpression in HPC7 cells did not produce significant changes in flt3 expression, 
although C/EBPα up regulation by 3.4 times was achieved (Figure 4.30 panel A); in 
a number of experiments the over expression of C/EBPα in FMH9 did not produce a 
great up regulation, while flt3 expression was markedly down regulated (Figure 4.30 
panel B). This may be explained by the fact that C/EBPα could induce leukaemic 
cells to differentiate, as previously published (Lidonnici et al, 2008), therefore losing 
the expression of flt3.    
 132 
 
Figure 4.29 Overexpression of c-myb.  Q-PCR analysis of c-myb and flt3 mRNA 
expression in HPC7 versus FMH9 after transfection with c-Myb expression vector or 
its relative empty control vector. Gapdh was used as the housekeeping control gene 
and each PCR reaction was performed for 40 cycles. These data are representative 
of a single experiment, with each PCR performed in triplicate. Results were 
confirmed in 3 to 4 independent experiments. The two-tailed p value was 
determined by paired t-test. Statistical significance: ***<0.001 and **<0.01. Error 
bars represent the standard error of the mean. 
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Figure 4.30 Overexpression of C/EBPα.  Q-PCR analysis of C/EBPα and flt3 
mRNA expression in HPC7 versus FMH9 after transfection with c-Myb expression 
vector or its relative empty control vector. Gapdh was used as the housekeeping 
control gene and each PCR reaction was performed for 40 cycles. These data are 
representative of a single experiment, with each PCR performed in triplicate. Results 
were confirmed in 3 to 4 independent experiments. The two-tailed p value was 
determined by paired t-test. Statistical significance: ***<0.001 and **<0.01.Error bars 
represent the standard error of the mean. 
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4.6 Histone modifying enzyme recruitment to flt3 
regulatory regions. 
The investigation of epigenetic modifications and transcription factor binding at the 
flt3 locus revealed a strict correlation between the interaction of c-Myb and C/EBPα 
with flt3 regulatory regions and the pattern of specific histone marks.  This could be 
explained by the fact that either c-Myb or C/EBPα recruit different histone modifying 
enzymes, leading to the increased expression of flt3 in AML-like cells.  This idea is 
supported by previous observations by Dai and colleagues who demonstrated the 
involvement of the histone acetyltransferase CBP (CREB-binding protein) as a co-
activator of c-Myb in the transcriptional regulation of several stem cell-related genes 
(Dai et al., 1996).  Another histone acetyltransferase, TIP60, has been shown to 
synergize with C/EBPα in myeloid differentiation and to be an important player in 
leukaemia (Bararia et al., 2008).  Hence, I next decided to investigate whether CBP 
and TIP60 were recruited at the flt3 locus in line with the presence of specific 
acetylation marks and the direct binding of c-Myb and C/EBPα to flt3 regulatory 
regions.  For this purpose, X-ChIP analysis was performed using specific antibodies 
against CBP and TIP60.  ChIP products were analyzed by real time PCR, focussing 
on the regions surrounding the cis-regulatory elements identified by DNAseI HSS 
assay, in order to determine the pattern for the recruitment of these histone-
modifying enzymes around these elements. The relative enrichment displayed in 
each plot of this section correspond to the ratio Bound specific IgG/Bound non-
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specific IgG (Pre-immune), obtained by subtracting the non-specific binding from the 
preimmune bound.   
4.6.1 CBP 
Analysis of anti-CBP immunoprecipitated DNA revealed no significant enrichment 
across the flt3 promoter/intron 1 region in HPC7 cells (Figure 4.31 upper panel).  A 
similar analysis performed on FMH9 cells highlighted a broader presence of this 
mark in the vicinity of the HS2 domain and downstream of the transcriptional start 
and most predominantly in the region immediately upstream the intronic HS5 
element (Figure 4.31 lower panel).  These findings reflect the difference in the 
acetylation status observed in FMH9 compared to the HPC7 cells, with the binding 
of CBP perfectly correlating with the peaks of H4K8ac (see section 4.4.2, Figure 4.8) 
around the regions of hypersensitivity of the flt3 locus. 
4.6.1 TIP60 
The analysis of DNA prepared from anti-TIP60 immunoprecipitated chromatin did 
not provide any evidence for a significant interaction of TIP60 with the flt3 locus in 
HPC7 cells, although a small degree of enrichment was seen at the transcription 
initiation site and in the vicinity of the intronic HS5 site (Figure 4.32 upper panel).  
However, a similar analysis of chromatin from FMH9 cells revealed an abundant 
binding of TIP60 around the regions encompassing the HS2, HS3 and HS4 domains 
and a large distribution around the HS5 element (Figure 4.32 lower panel), in 
agreement with the presence of the peak of H3K9 acetylation (Figure 4.9) and the 
predominance of H4K8 acetylation across the flt3 locus (Figure 4.8). 
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Figure 4.31 In vivo binding of CBP at the flt3 locus. X-ChIP experiments were 
performed on chromatin derived from both HPC7 and FMH9 cell lines using an 
antibody anti-CBP.  Purified immunoprecipitated DNA was used as a template for Q-
PCR amplifications to determine the relative enrichment compared to the control IgG 
ChIP material.  The plots represent the relative enrichment on the Y-axis and the 
position relative to the transcriptional start site on the X-axis.  The figure shows the 
alignment of the histograms with a schematic representation of the flt3 promoter and 
first intron.  DNAseI HSSs are indicated by red arrows. Dashed line represent the 
basal level across the locus. The width of the bars in the plot reflects the length of 
the amplicons. PCR amplicons overlap as indicated. This figure represents the 
typical result obtained in two independent experiments in which each PCR was 
performed in triplicate from one ChIP experiment. Error bars represent the standard 
error of the mean. 
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Figure 4.32 In vivo binding of TIP60 at the flt3 locus. X-ChIP experiments were 
performed on chromatin derived from both HPC7 and FMH9 cell lines using an 
antibody anti-TIP60.  Purified immunoprecipitated DNA was used as a template for 
Q-PCR amplifications to determine the relative enrichment compared to the control 
IgG ChIP material.  The plots represent the relative enrichment on the Y-axis and 
the position relative to the transcriptional start site on the X-axis.  The figure shows 
the alignment of the histograms with a schematic representation of the flt3 promoter 
and first intron.  DNAseI HSSs are indicated by red arrows. Dashed line represent 
the basal level across the locus. The width of the bars in the plot reflects the length 
of the amplicons. PCR amplicons overlap as indicated. This figure represents the 
typical result obtained in two independent experiments in which each PCR was 
performed in triplicate from one ChIP experiment. Error bars represent the standard 
error of the mean. 
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CHAPTER 5: DISCUSSION AND FUTURE 
WORK 
 
5.1 Discussion  
The last decade has seen a growing interest in the extent to which the receptor 
tyrosine kinase Flt3 is involved in both expansion and survival of HSCs, progenitors 
and leukaemic cells (Brasel et al 1995: Turner et al, 1996).  Recently, Adolfsson and 
colleagues have demonstrated that the expression pattern of the Flt3 receptor can 
be used to distinguish the early stages of commitment of HSCs in the bone marrow 
compartment, since it is up regulated as the cells transit from LT-HSCs to ST-HSCs 
and MPPs, followed by rapid down regulation as MPP differentiation takes place 
(Adolfsson et al, 2001; Adolfsson et al, 2005).  Furthermore, a flurry of publications 
has underlined the association of high-level expression of Flt3 with a broad 
spectrum of haematological malignancies (reviewed by Gilliland DG, 2002).  At 
present, very little is known about the mechanisms associated with the 
transcriptional up regulation of flt3 gene expression in HSCs or how the alteration of 
such mechanisms may trigger the persistent activation of the gene, either in its wild 
type or mutated form, in a wide range of leukaemias.  To date, the mechanistic 
differences that might distinguish normal flt3 expression in HSCs from that seen in 
leukaemic cells are still unclear and subject of debate. 
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Since the outset of the investigations described in this thesis, there were two 
questions to be addressed: 1. How is flt3 gene transcription regulated in normal 
HSCs and 2. What mechanistic differences lead to the persistent expression of flt3 
in leukaemic cells?  Data presented in this thesis have led to the identification of 
regions of the flt3 gene that show features of regulatory activity in relation to its 
expression, and to a definition of the epigenetic environment and the composition of 
potential transcription factor complexes interacting with them in vivo in both stem 
cells and leukaemic cells.  
Using two independent DNAseI hypersensitive site mapping approaches (Southern 
blot and a Q-PCR-based approach), I have identified five candidate cis-regulatory 
regions in the flt3 locus. Initially, the Southern blot approach was used in order to 
scan a large part of the gene that showed sequence conservation (see Figure 3.1). 
Although it is widely applied, the Southern blot approach is not quantitative and it 
has numerous technical limitations, such as being low-throughput and lacking of 
sequence specificity, as it is an indirect assay. Thus the Q-PCR approach, which is 
a quantitative, high-throughput, direct assay, was subsequently used to investigate 
more precisely the regions of hypersensitivity and to identify potential cis-regulatory 
domains. This latter analysis was also extended to sorted cells in order to confirm 
the presence of these regulatory regions in primary cells. Only two of the five 
domains, HS3 and HS5, appear to be significantly active in primary Flt3-KSL (LT- 
and ST-HSC) and Flt3+KSL (MPP) cells, with the intronic (HS5) regulatory element 
becoming active during the transition between the Flt3- and the Flt3+ states.  The 
importance of the HS3 and HS5 regions was emphasized by the characterization of 
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the epigenetic environment of the flt3 locus.  Hence, ChIP analysis of the acetylation 
(H3K9ac, H4K8ac) and methylation (H3K4me3, H3K9me2) status of the flt3 
promoter and intronic regions revealed considerable differences in the pattern of 
these epigenetic modifications (Figure 5.1).  Interestingly, a large peak of H3K9 
acetylation was detected in the vicinity of the HS5 intronic element (Figure 4.9). An 
apparent broad enrichment of H4K8 acetylation was seen only in the leukaemia-like 
cells, while H3K4me3 was differentially distributed in the vicinity of the 
hypersensitive sites. Importantly, this analysis revealed the predominance of several 
active histone marks around the intronic HS5 domain (Figure 5.1), which could point 
to a role of the intronic domain as an enhancer. The epigenetic features observed 
around the HS5 intronic region could also indicate the presence of an alternative 
promoter, although there is no evidence of any flt3 transcript other than that 
originating at exon1. Whether the HS5 regulatory region is an enhancer or an 
alternative promoter is yet to be determined and this will be further investigated by 
performing Polymerase II ChIP and RACE PCR analysis. 
In order to assess the link between the epigenetic modifications observed and the in 
vivo binding of specific transcription factors in stem cells versus leukaemic cells, I 
carried out a bioinformatic analysis to identify potential protein binding sequences 
encompassed by the DNAseI hypersensitive regions and then performed X-ChIP 
experiments for a selected set of transcription factors that could be potentially 
recruited there.   
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Figure 5.1 Epigenetic modification of the flt3 gene in haematopoietic stem 
cells versus leukaemic cells. This figure shows the differential distribution of 
histone marks around the candidate cis-regulatory elements of the flt3 gene. HSSs 
are indicated with red numbers and are aligned to the flt3 schematic. The black 
boxes represent exon1 and 2, with the black arrow indicating the transcriptional start 
site. Histon modifications are represented with a colour code: H3K4me3 in yellow, 
H48ac in red, H3K9ac in green and H3K9me2 in blue. The size of each symbol is 
representative of the relative enrichment of each mark (see section 4.5) 
 
This analysis, performed in the HSC-like HPC7 cell line, revealed the binding of 
multiple transcription factors on HS3 and HS5, including some of the crucial 
regulators of stem cell maintenance, proliferation and commitment, many of which 
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are also key players in leukaemogenesis. Following the identification of several 
conserved consensus binding sites for Ets and GATA factors, ChIP analysis 
demonstrated the direct interaction of PU.1 and GATA1/2 with the HS3 domain, with 
GATA1 also binding to HS2 and HS5. The analysis of GATA factors was only 
performed in HSC-like cells, since their expression was not detected in FMH9, while 
no interaction of PU.1 with flt3 locus was observed in FMH9. Importantly, ChIP 
analysis revealed the binding of C/EBPα and c-Myb, both of them directly interacting 
with the flt3 locus on HS3 and HS5 elements. Given the demonstration of an 
important role for HoxA9, Meis1 and Pbx1/2 in the regulation of flt3 (Wang et al.; 
2006), the direct association of these transcription factors with the flt3 gene was 
investigated, and with the exception of Pbx2, each of them was observed to be 
bound to the HS3 domain in HSC-like cells.  
Some of the transcription factors shown to interact with flt3 regulatory regions 
appeared to be doing so even though their consensus binding sites are not present. 
This was the case for Runx1 (Figure 4.25) and MLL (Figure 4.26), suggesting that 
the in vivo binding of these two transcription factors may be mediated by one or 
more other protein that are directly recruited to the HS3 and HS5 regions.  
Comparative ChIP analysis between HPC7 and FMH9 cells revealed striking 
differences in the transcription factor occupancy of the flt3 gene in stem cells and 
leukaemic cells. Although Mesi1, HoxA9, Pbx1 and c-Myb ChIP revealed a similar 
profile in both cell types, the recruitment of C/EBPα was noticeably different, being 
present in HS3 and HS5 in HPC7 cells, but only on the intronic HS5 element in 
AML-like FMH9 cells. Furthermore, unlike the situation in HPC7 cells, no in vivo 
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binding of PU.1, Runx1 or MLL was detected in AML-like cells. The binding of MLL 
was of particular interest, as the in vivo interaction of this transcription factor in 
HPC7 correlates with the presence of the H3K4me3 histone mark. In fact, in HPC7 
cells this mark was found enriched both upstream and downstream of the HS3 
region and upstream the HS5 region, where MLL was shown to be recruited on the 
flt3 locus (Figure 4.26). No such correlation was observed in FMH9, since MLL 
binding on the flt3 gene was not detected in the leukaemic cells. However, it is worth 
noting that MLL ChIP analysis was performed using an antibody against the C-
terminus of MLL and recently it has been observed that MLLC, unlike MLLN, could 
not be detected in leukaemic cells (personal communication). Therefore, further 
ChIP analysis using an N-terminal MLL antibody will be needed to follow up on the 
observations in FMH9 cells.   
The ChIP data for transcription factor binding to the flt3 locus collectively suggests a 
crucial role for Meis1, HoxA9, C/EBPα and c-Myb in the leukaemic context.  Some 
of these latter transcription factors have been shown to synergize in the regulation of 
specific genes.  For example, it was demonstrated that c-Myb, C/EBPα and PU.1 
cooperate in the activation of the neutrophil elastase (NE) promoter in myeloid cells 
(Oelgeshlager et al., 1996) and on the promoter of the avian myeloid gene mim-1 
(Burk et al., 1993; Dudek et al., 1992; Ness et al., 1993).  Some of these 
transcription factors can also exert antagonistic effects, as demonstrated by Soliera 
and co-workers who have recently established a connection between the 
transcriptional repression of c-Myb- and C/EBPα-mediated differentiation of 
leukaemia-like stem cells.  The downregulation of c-myb mRNA levels was seen 
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upon C/EBPα activation with consequent differentiation of K562 cells, while c-Myb 
expression instead resulted in C/EBPα downregulation and differentiation arrest 
(Soliera et al, 2008).  However, as the latter authors suggested, this effect seemed 
to be dependent on the cell context.  In fact, in the AML cell model used here, the 
downregulation of c-myb did not produce an effect on C/EBPα activity, nor did the 
overexpression of C/EBPα result in significant down regulation of c-myb RNA levels 
(data not shown).  However, this suggests that there is a tight balance between 
different transcription factors that must be maintained in normal stem cells, the 
alteration of which may result in leukaemogenesis.  
The analysis of in vivo transcription factor binding also revealed that GATA1, 
GATA2 and PU.1 are recruited to the flt3 promoter in HSCs, but appear to be 
dispensable for flt3 regulation in leukaemic cells, clearly indicating the involvement 
of different transcription factor complexes in AML cells compared to normal HSCs 
(Figure 5.2).  Whether this is a reflection of the leukaemic state or the stage myeloid 
lineage differentiation still needs to be elucidated, and this will be pursued through 
the analysis of transcription factors complexes recruited to the flt3 promoter in 
normal myeloid progenitors.  
The potential role of C/EBPα in flt3 gene regulation is particularly interesting as it 
exhibits in vivo binding to HS3 and HS5 in HSCs, while in AML-like cells its 
interaction with the flt3 locus was restricted to the intronic domain.  C/EBPα function 
during commitment towards myeloid progenitors mainly involves the repression of 
gene expression (Zhang et al 1997; Radomska et al, 1998; Keeshan  et al, 2003) 
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and the loss of C/EBPα expression or activity is an important requirement for 
leukaemogenesis (Tenen DG, 2003). 
 
Figure 5.2. Transcription factor binding to the flt3 gene in haematopoietic 
stem cells versus leukaemic cells. This figure shows the differential in vivo 
binding of specific transcription factors to the candidate cis-regulatory elements of 
the flt3 gene in HSC-like and AML-like cells. HSSs are indicated with red numbers 
and are aligned to the flt3 schematic. The black boxes represent exon1 and 2, with 
the black arrow indicating the transcriptional start site. 
 
C/EBPα mutations have been identified in 10% of AML patient and several studies 
have demonstrated a higher overall survival in those cases.  The most common 
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alteration to C/EBPα expression consists of the loss of the full-length 42kDa isoform 
(p42), which regulates the proliferation of myeloid progenitors, and the retention of 
the oncogenic 30kDa isoform (p30), which functions principally by sumoylating p42, 
thus decreasing its transactivation capacity (Kirstetter et al., 2008; Geletu et al., 
2007).  I investigated the presence of both isoforms in the FMH9 and HPC7 cell 
lines by performing a Western blot analysis (data not shown); this revealed that the 
p42 isoform is predominant in both cell types. 
The relative importance of c-Myb and C/EBPα function in flt3 regulation was further 
examined by a combination of shRNA-mediated knock down and overexpression.  
These studies revealed an important role for c-Myb as its down-regulation produced 
a significant decrease in flt3 RNA in both cell lines, while C/EBPα seemed to exert 
an important function in AML-like cells only, flt3 expression being unaffected by 
C/EBPα shRNA-mediated knock down in HPC7 (see Figure 4.30).  The 
overexpression of c-Myb in HPC7 cells did not induce a change in flt3 mRNA levels, 
whereas in FMH9 cells it resulted in a large induction of flt3 expression.  Similarly, 
C/EBPα activation did not induce a significant up-regulation of flt3 expression in 
HPC7.  Several attempts to over express C/EBPα in FMH9 cells only resulted in a 
small increase in the level of this transcription factor, but this seemed to be sufficient 
to achieve a consistent and large down-regulation of flt3 mRNA.  This latter 
observation could be explained by the propensity of C/EBPα to induce monocytic 
differentiation in leukaemic cells, as already observed in K562 and in leukaemic 
CD34+ stem progenitor cells (Soliera et al, 2009; Schepers et al, 2007; Matsushita et 
al, 2008), or it may reflect a perturbation of the tight balance between the expression 
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of c-Myb and C/EBPα that is needed for the enhanced flt3 expression in FMH9 cells. 
As mentioned in section 4.5.3, data for shRNA knock down and overexpression 
experiments presented in this thesis have been analysed by Q-PCR only, due to the 
lack of sufficient cell numbers to allow protein analysis by western blot. Having 
defined a correlation on the flt3 locus between the epigenetic environment and the in 
vivo binding of c-Myb and C/EBPα, as well as the relative importance of these two 
transcription factors in the regulation of the gene, I next tried to understand how c-
Myb and C/EBPα contribute to the establishment of the epigenetic environment in 
leukaemia-like cells (see Figure 5.1).  The hypothesis that c-Myb and C/EBPα both 
act to recruit specific chromatin modifying enzymes responsible for the deposition of 
acetyl marks over the flt3 locus in FMH9 cells is supported by the demonstration that 
the acetyltransferases CBP and TIP60 function as co-activators of c-Myb and 
C/EBPα, respectively (Figure 5.3).  In fact, Pattabiraman and colleagues reported 
that mutations in the CBP c-Myb binding domains disturb the interaction of c-Myb 
with CBP/p300, abrogating its ability to transform myeloid cells (Pattabiraman et al, 
2009).  Similarly, Bararia and co-workers demonstrated a requirement for TIP60 in 
C/EBPα function in myeloid differentiation and leukaemia (Bararia et al, 2008). 
Therefore, the higher level of acetylation observed on the flt3 locus in FMH9 cells 
compared to HPC7 cells could be brought about by CBP and TIP60, recruited by c-
Myb and C/EBPα, respectively (Figure 5.3).  
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Figure 5.3. Model for recruitment of histone modifying enzymes to the 
promoter of target genes. This figure summarises the observation obtained by 
Bararia (Bararia et al., 2008) and Pattabiraman (Pattabiraman et al., 2009), who 
have demonstrated that c-Myb (blue) and C/EBPα (purple), recruit CBP (orange) 
and TIP60 (dark grey), respectively, to the promoter region of target genes. These 
co-factors are histone acetyltransferases, hence being responsible for the deposition 
of the acetyl marks (Ac, indicated in read). 
 
Interestingly, ChIP analysis in FMH9 for CBP and TIP60 revealed a similar pattern 
for the recruitment of these two histone modifying enzymes to the flt3 locus, while no 
interaction with the promoter or intronic region was observed in HPC7 cells. Notably, 
the binding observed for CBP mirrors precisely the pattern of H4K8 acetylation 
observed in FMH9 cells: analysis of both CBP and TIP60 revealed a large peak of 
binding in the vicinity of the intronic element, co-localizing with H3K9 acetylation. 
Furthermore, the recruitment of CBP and TIP60 also co-localises with the in vivo 
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binding of both c-Myb and C/EBPα (Figure 5.4): Whether this co-localization is a 
direct consequence of c-Myb and C/EBPα binding to the flt3 locus still remains to be 
elucidated.  
This analysis points to a potential role for CBP and TIP60 in the establishment or 
maintenance of the higher acetylation status observed in the leukaemic context. 
Whether these two acetyltransferases are the main effectors still needs to be 
clarified, and this will be assessed initially by performing shRNA analysis of CBP 
and TIP60 followed by ChIP analysis for both H3K9 and H4K8 acetylation.    
Altogether, the data presented in this thesis show that defining the details of 
epigenetic and transcriptional regulation underlying flt3 expression can help to 
elucidate the mechanisms that dictate not only the commitment and differentiation of 
normal haematopoietic stem cells, but may also shed light on the processes that 
lead to lineage-restricted cells assuming a leukaemic fate.  
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Figure 5.4. Epigenetic and transcriptional regulation of the flt3 gene in 
haematopoietic stem cells versus leukaemic cells. This figure shows the 
differential distribution of histone marks around the candidate cis-regulatory 
elements of the flt3 gene, together with the binding of transcription factors c-Myb 
(blue) and C/EBPα (purple). This figure also shows the differential recruitment of 
acetyl transferases CBP (orange) and TIP60 (black) in the leukaemic context. HSSs 
are indicated with red numbers and are aligned to the flt3 schematic. The black 
boxes represent exon1 and 2, with the black arrow indicating the transcriptional start 
site. Histone modifications are represented with a colour code: H3K4me3 in yellow, 
H48ac in red, H3K9ac in green and H3K9me2 in blue. The size of each symbol is 
representative of the relative enrichment of each mark (see section 4.5) 
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5.2 Future directions 
Having identified several regions of hypersensitivity that correlate with the presence 
of epigenetic marks indicative of active transcription as well as the in vivo binding of 
stem cell-related transcription factors, it would be of interest to investigate the 
relative contribution of each of the candidate regulatory elements identified to the 
regulation of the flt3 gene. For this purpose it will be necessary to perform transient 
transfection assays using promoter-reporter constructs. These constructs will be 
engineered by linking the promoter either alone or in combination with the intronic 
element respectively upstream and downstream of the luciferase reporter gene. The 
importance of each regions of hypersensitivity in the promoter and intronic region 
will be established by generating specific deletions and point mutations in each of 
them. 
My observations on the differential distribution of active histone epigenetic marks 
around the intronic HS5 element has led to the hypothesis that this region could 
either be an enhancer of flt3 transcription or an alternative promoter. In order to 
resolve these possibilities, ChIP analysis for H3K4me1 and p300 will need to be 
performed to assess if the intronic region acts as an enhancer, while ChIP for 
Polymerase II, in parallel with the RACE PCR, will help to determine the existence of 
any alternative transcription start site.  
It would be interesting also to assess the relative importance of CBP and TIP60. 
ChIP-ReChIP analysis will be performed in order to determine the direct association 
of c-Myb with CBP and of C/EBPα with TIP60 on the flt3 regulatory regions. To 
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investigate whether CBP and TIP60 are responsible for the higher acetylation status 
observed in FMH9 cells, shRNA knock down experiments of CBP and TIP60 will be 
performed, followed by ChIP analysis of H4K8 and H3K9 acetylation. 
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